

Q1 **Anaesthetic–analgesic ear drops to reduce antibiotic consumption in children with acute otitis media: the CEDAR RCT**

Q2,Q3

Alastair D Hay,^{1*} Harriet Downing,² Nick A Francis,³ Grace J Young,⁴ Clare Clement,⁴ Sue D Harris,¹ Aideen Ahern,⁴ Behnaz Schofield,³ Tammy E Thomas,⁵ Jeremy Horwood,^{1,4} Peter S Blair,⁴ William Hollingworth,⁶ Victoria Wilson,¹ Chris Metcalfe,⁴ Peter Stoddart,⁷ Desmond Nunez,⁸ Mark D Lyttle,⁷ Paul Little⁵ and Michael V Moore⁵

¹Centre for Academic Primary Care, Bristol Medical School, Department of Population Health Sciences, University of Bristol, Bristol, UK

²National Institute for Health Research Biomedical Research Centre, Bristol Medical School, Department of Population Health Sciences, University of Bristol, Bristol, UK

³Division of Population Medicine, Cardiff University, Cardiff, UK

⁴Bristol Randomised Trials Collaboration, Bristol Medical School, Department of Population Health Sciences, University of Bristol, Bristol, UK

⁵Primary Care and Population Sciences, University of Southampton, Southampton, UK

⁶Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, UK

⁷Bristol Royal Hospital for Children, Bristol, UK

⁸Division of Otolaryngology, Department of Surgery, The University of British Columbia, Vancouver, BC, Canada

*Corresponding author

Declared competing interests of authors: Alastair D Hay and William Hollingworth are members of the Health Technology Assessment Clinical Trials Board. Chris Metcalfe is a member of a clinical trials unit in receipt of National Institute for Health Research (NIHR) support funding. Desmond Nunez is an author of a related Cochrane review protocol. Paul Little is the Director of the NIHR Programme Grants for Applied Research programme and a member of the NIHR Journals Library Board.

Published XXXX 2018

DOI: 10.3310/hta22XXX

This report should be referenced as follows:

Hay AD, Downing H, Francis NA, Young GJ, Clement C, Harris SD, *et al.* Anaesthetic–analgesic ear drops to reduce antibiotic consumption in children with acute otitis media: the CEDAR RCT. *Health Technol Assess* 2018;**22**(XX).

Health Technology Assessment is indexed and abstracted in *Index Medicus/MEDLINE*, *Excerpta Medica/EMBASE*, *Science Citation Index Expanded (SciSearch®)* and *Current Contents®/Clinical Medicine*.

ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 4.513

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nhr.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nhr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nhr.ac.uk

Criteria for inclusion in the *Health Technology Assessment* journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: <http://www.nets.nhr.ac.uk/programmes/hta>

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 13/88/13. The contractual start date was in January 2015. The draft report began editorial review in January 2018 and was accepted for publication in June 2018. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen's Printer and Controller of HMSO 2018. This work was produced by Hay *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nhr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

NIHR Journals Library Editor-in-Chief

Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

NIHR Journals Library Editors

Professor Ken Stein Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andrée Le May Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson Director of the NIHR Dissemination Centre, University of Southampton, UK

Ms Tara Lamont Scientific Advisor, NETSCC, UK

Dr Catriona McDaid Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Professor of Wellbeing Research, University of Winchester, UK

Professor John Norrie Chair in Medical Statistics, University of Edinburgh, UK

Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk

Abstract

Anaesthetic–analgesic ear drops to reduce antibiotic consumption in children with acute otitis media: the CEDAR RCT

Alastair D Hay,^{1*} Harriet Downing,² Nick A Francis,³ Grace J Young,⁴ Clare Clement,⁴ Sue D Harris,¹ Aideen Ahern,⁴ Behnaz Schofield,³ Tammy E Thomas,⁵ Jeremy Horwood,^{1,4} Peter S Blair,⁴ William Hollingworth,⁶ Victoria Wilson,¹ Chris Metcalfe,⁴ Peter Stoddart,⁷ Desmond Nunez,⁸ Mark D Lyttle,⁷ Paul Little⁵ and Michael V Moore⁵

¹Centre for Academic Primary Care, Bristol Medical School, Department of Population Health Sciences, University of Bristol, Bristol, UK

²National Institute for Health Research Biomedical Research Centre, Bristol Medical School, Department of Population Health Sciences, University of Bristol, Bristol, UK

³Division of Population Medicine, Cardiff University, Cardiff, UK

⁴Bristol Randomised Trials Collaboration, Bristol Medical School, Department of Population Health Sciences, University of Bristol, Bristol, UK

⁵Primary Care and Population Sciences, University of Southampton, Southampton, UK

⁶Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, UK

⁷Bristol Royal Hospital for Children, Bristol, UK

⁸Division of Otolaryngology, Department of Surgery, The University of British Columbia, Vancouver, BC, Canada

*Corresponding author alastair.hay@bristol.ac.uk

Background: Acute otitis media (AOM) is a common reason for primary care consultations and antibiotic prescribing in children. Options for improved pain control may influence antibiotic prescribing and consumption.

Q4 Objective: The children's drops for ear pain in AOM (CEDAR) trial investigated whether providing anaesthetic–analgesic ear drops reduced antibiotic consumption in children with AOM. Secondary objectives included pain control and cost-effectiveness.

Design: Multicentre, randomised, parallel group (two-group initially then three-group) trial.

Setting: Primary care practices in England and Wales.

Participants: 1- to 10-year old children, presenting within 1 week of suspected AOM onset, with ear pain during the preceding 24 hours, and not requiring immediate antibiotics. Participating children were logged into the study and allocated using a remote randomisation service.

Interventions: Two-group trial: unblinded comparison of anaesthetic–analgesic ear drops versus usual care. Three-group trial: blinded comparison of anaesthetic–analgesic ear drops versus placebo ear drops; and unblinded comparison with usual care.

Main outcome measures: The primary outcome measure was parent reported antibiotic use by the child over 8 days following enrolment. Secondary measures included ear pain at day 2 and NHS and societal costs over 8 days.

Results: Owing to a delay in provision of the placebo drops, the recruitment period was shortened and most participants were randomly allocated to the two-group study ($n = 74$) rather than the three-group study ($n = 32$). Comparing active drops to usual care in the combined two-group and three-group studies, 1 out of 39 (3%) children allocated to the active drops group and 11 out of 38 (29%) children allocated to the usual-care group consumed antibiotics in the 8 days following enrolment [unadjusted odds ratio 0.09, 95% confidence interval (CI) 0.02 to 0.55; $p = 0.009$; adjusted for delayed prescribing odds ratio 0.15, 95% CI 0.03 to 0.87; $p = 0.035$]. A total of 43% (3/7) of patients in the placebo drops group consumed antibiotics by day 8 compared with 0% (0/10) in the three-group study active drops groups ($p = 0.051$). The economic analysis of NHS costs (£12.66 for active drops and £11.36 for usual care) leads to an estimated cost of £5.19 per antibiotic prescription avoided, but with a high degree of uncertainty. A reduction in ear pain at day 2 in the placebo group ($n = 7$) compared with the active drops group ($n = 10$) (adjusted difference in means 0.67, 95% CI -1.44 to 2.79; $p = 0.51$) is consistent with chance. No adverse events were reported in children receiving active drops.

Q5 **Limitations:** Estimated treatment effects are imprecise because the sample size target was not met. It is not clear that delayed prescriptions of an antibiotic were written prior to randomisation. Few children received placebo drops, which hindered the investigation of ear pain.

Conclusions: This study suggests that reduced antibiotic use can be achieved in children with AOM by combining a no or delayed antibiotic prescribing strategy with anaesthetic–analgesic ear drops. Whether or not the active drops relieved ear pain was not established.

Future work: The observed reduction in antibiotic consumption following the prescription of ear drops requires replication in a larger study. Future work should establish if the effect of ear drops is due to pain relief.

Trial registration: Current Controlled Trials ISRCTN09599764.

Funding details: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 22, No. X. See the NIHR Journals Library website for further project information. Alastair D Hay was funded by a NIHR Research Professorship (NIHR-RP-02-12-012).

Q6

Contents

List of tables	xi
List of figures	xiii
List of abbreviations	xv
Plain English summary	xvii
Scientific summary	xix
Chapter 1 Introduction	1
Structure of this report	1
Background	1
Literature review	1
Study aim	2
Specific research questions	2
Chapter 2 Methods	3
Study design	3
Recruitment sites and site training	3
Participants and recruitment	3
<i>Eligibility</i>	3
<i>Changes to the eligibility criteria</i>	5
Interventions	5
Outcomes	5
<i>Primary outcome</i>	5
<i>Secondary outcomes</i>	5
Sample size	7
Random allocation	7
Blinding	8
Statistical methods	8
<i>Statistical primary analysis</i>	8
<i>Statistical secondary analyses</i>	8
<i>Sensitivity analyses</i>	8
<i>Subgroup analyses</i>	9
<i>Exploratory analyses</i>	9
Health economic methods	9
Qualitative methods	10
<i>Sampling</i>	10
<i>Interview conduct</i>	10
<i>Qualitative data analysis</i>	11
Chapter 3 Results	13
Study progress	13
Recruitment and completion of follow-up assessments	13
Baseline data	15

Outcomes and estimation	19
<i>Primary outcome: antibiotic consumption</i>	19
<i>Key secondary outcome: ear pain on day 2</i>	20
<i>Secondary outcome: ear pain on day 1</i>	20
<i>Secondary outcome: oral analgesic consumption</i>	21
<i>Secondary outcome: overall symptom burden</i>	22
<i>Secondary outcome: overall illness duration</i>	24
<i>Secondary outcome: time to antibiotic consumption</i>	24
<i>Secondary outcome: adverse events</i>	24
<i>Secondary outcome: parent satisfaction</i>	25
Sensitivity analyses	26
<i>Per-protocol analysis</i>	26
<i>Sensitivity analysis: missing data imputed under best- and worst-case scenarios</i>	26
<i>Sensitivity analysis: exclusion of children found to be ineligible following allocation</i>	27
<i>Exploratory analysis: reported pain by antibiotic use</i>	27
Subgroup analyses	27
Health economic results	28
<i>Cost-effectiveness findings</i>	28
<i>Other outcomes</i>	29
Qualitative data results	30
<i>Number and characteristics of parents</i>	30
<i>Views and experiences of trial</i>	30
<i>Reasons for and experiences of consulting</i>	32
<i>Views and experience of treatments</i>	33
Chapter 4 Discussion	35
Summary of main findings	35
Strengths and weaknesses	35
Comparison with other literature	37
Implications for policy, clinical practice and research	37
Conclusion	38
Acknowledgements	39
References	43
Appendix 1 Recruitment to the CEDAR trial	45

List of tables

TABLE 1 Further details on data available for antibiotic consumption and pain outcome measures	15
TABLE 2 Baseline characteristics by allocated group, two-group study	16
TABLE 3 Clinical characteristics at presentation by allocated group, two-group study	16
TABLE 4 Baseline characteristics by allocated group, three-group study	17
TABLE 5 Clinical characteristics at presentation by allocated group, three-group study	18
TABLE 6 Primary analysis: antibiotic consumption, by group	19
TABLE 7 The impact of giving a delayed antibiotic script on consumption of antibiotics, by group	19
TABLE 8 Key secondary analysis: ear pain score on day 2, by group	20
TABLE 9 Exploratory analysis: ear pain on day 2, by group	20
TABLE 10 Secondary analysis: ear pain on day one (approximately 1 hour after administering the drops), by group	20
TABLE 11 Secondary analysis: analgesic consumption, by group	21
TABLE 12 Secondary analysis: number of doses of oral analgesic, by group	22
TABLE 13 Secondary analysis: overall symptom burden over 8 days, quantified as the area under the curve, by group	23
TABLE 14 Overall duration of pain	24
TABLE 15 Sensitivity analysis: per-protocol analysis excluding from the two-group study, one child who did not meet the compliance criterion for the study medication – antibiotic consumption, by group	26
TABLE 16 Sensitivity analysis with missing data imputed under best- and worst-case scenarios: antibiotic consumption, by group	26
TABLE 17 Sensitivity analysis with two children found to be ineligible removed: Antibiotic consumption, by group	27
TABLE 18 Subgroup variations in the effect of active drops vs. usual care on whether or not children consumed antibiotics	28
TABLE 19 Unit costs of resource valuation	28
TABLE 20 Health care and time off work costs, days 1–8, by group	29

TABLE 21 The CHU-9D scores, by group	29
TABLE 22 Days off school or preschool childcare, by group	29
TABLE 23 Interviewee characteristics	30

List of figures

FIGURE 1 The CEDAR trial three-group randomised study with observational cohort study	3
FIGURE 2 Parent-completed assessment of pain	6
FIGURE 3 The CEDAR trial CONSORT (Consolidated Standards of Reporting Trials) flow chart	14
FIGURE 4 Mean pain scores by day and group, combining the two- and three-group children and including only those with full 8 days' data on ear pain	21
FIGURE 5 Analgesic consumption up to day 8 for the two- and three-group studies	22
FIGURE 6 Mean symptom burden in the two-group [(a) and (b)] and three-group studies [(c), (d) and (e)]	22
FIGURE 7 Kaplan Meier curve for the time to recovery from pain in the two-group trial	24
FIGURE 8 By trial group: what would you want to use for your child for a similar illness in the future?	25
FIGURE 9 Mean pain scores by day and antibiotic consumption, combining the two- and three-group children and only including those with full 8-day data on ear pain	27
FIGURE 10 Projected and actual recruitment to the CEDAR trial, October 2016 to April 2017	45

Q7 List of abbreviations

AOM	acute otitis media	IMP	investigational medicinal product
BNF	<i>British National Formulary</i>	ITT	intention to treat
CEDAR	Children's Ear Pain Study	NICE	National Institute for Health and Care Excellence
CI	confidence interval	NIHR	National Institute for Health Research
DAEN	Database of Adverse Event Notifications	RCT	randomised controlled trial
G6PD	glucose-6-phosphate dehydrogenase	REDCap	Research Electronic Data Capture
GP	general practitioner	SD	standard deviation
ID	identifier		

Plain English summary

Ear infections are common in children < 10 years of age, with 40% of these children suffering with an ear infection at least once per year. During the infection, germs multiply in the confined space of the middle ear resulting in a build-up of pressure that pushes on and stretches the ear drum. This causes severe pain and distress to the child, in turn leading to disrupted family life.

Although there is world class evidence showing that antibiotics do not help, and the National Institute for Health and Care Excellence advise against their use, > 85% of UK children with middle ear infections (acute otitis media) are prescribed an antibiotic, which is a higher percentage than for any other childhood infection. Antibiotics do not treat the child's pain, and in most cases they do not help to treat the infection (because many ear infections are caused by viruses that do not respond to antibiotics), but they can cause side effects (such as diarrhoea) and increase the problem of antibiotic resistance, which is a major public health concern.

Q9 The Children's Ear Pain Study (CEDAR) wanted to find out whether or not painkilling ear drops (Auralgan™, currently manufactured by Pfizer Consumer Healthcare) can, by treating children's ear pain, reduce the number of parents giving their children antibiotics for acute otitis media. Children were given the painkilling drops, placebo (dummy) drops or usual care. We found that if the children were given the painkilling drops, significantly fewer of them were given antibiotics. **Q8**

Unfortunately, there were not enough children who took part in the study to change advice on how doctors treat ear infections. However, we think these results suggest that ear drops help reduce unnecessary antibiotic use and should be investigated in a further larger study.

Scientific summary

Background

Q10

Acute otitis media (AOM) is a common, painful condition of childhood that has an impact on the family because of disrupted sleep and time off work and school. Primary care consultation and antibiotics have been the mainstay of management; one UK study found that between 80% and 84% of children presenting to primary care with AOM were prescribed an antibiotic during the years 1995–2011. This is despite the available evidence of benefit being restricted to children < 2 years old with bilateral AOM, and those with otorrhoea, leading the National Institute for Health and Care Excellence (NICE) to conclude that these are the only children warranting a same-day full-course antibiotic treatment. For other children, the use of a 'wait-and-see' strategy, with or without a delayed prescription for an antibiotic, has been shown to be safe in terms of treatment failure and in the frequency of complications of AOM. Selective antibiotic prescribing in AOM is also recommended by other national guidelines, including the American Academy of Family Physicians and American Academy of Pediatrics, Dutch College of General Practitioners, Scottish Intercollegiate Guideline Network, and French Health Products Safety Agency.

Judicious use of antibiotics seeks not only to counter the risks of antibiotic side effects (such as diarrhoea, rashes and anaphylaxis) but to also counter the risk of increasing antibiotic-resistant bacterial strains, which have been shown to increase substantially after antibiotic use. In view of AOM's prevalence, and the high associated antibiotic use, strategies to facilitate a reduction in antibiotic use in this condition in the UK are urgently required. Anaesthetic–analgesic ear drops are widely used in some countries and, if effective for controlling ear pain, could reduce dependence on antibiotics. However, there is little evidence regarding their effectiveness as an analgesic, and no evidence on how their use affects antibiotic consumption.

Objectives

The primary aim of the study was to determine if providing topical anaesthetic–analgesic drops (Auralgan™) leads to a reduction in antibiotic consumption within the first 8 days of AOM diagnosis.

The secondary objectives were to answer the following questions:

- Are anaesthetic–analgesic ear drops more effective than placebo (key secondary question) and usual care in controlling AOM ear pain?
- Are children and their parents satisfied with using ear drops?
- Are anaesthetic–analgesic ear drops cost-effective?
- Do the drops improve the child's quality of life?
- What are the parents' beliefs and expectations in relation to AOM and its treatment?

Methods

The Children's Ear Pain Study (CEDAR) was a multicentre, randomised three-group (anaesthetic–analgesic drops, placebo drops and usual care) randomised controlled trial (RCT). Owing to investigational medicinal product (IMP) supply problems, recruitment was initially to a two-group (anaesthetic–analgesic drops vs. usual care) RCT. General practice surgeries in the primary care research network within the areas of Bristol, Cardiff and Southampton agreed to participate. The study was co-ordinated by the Bristol study centre.

Children were eligible if they met all the following criteria:

- Were aged between 12 months and 9 years.
- Presented within 1 week of suspected AOM onset.
- Had parent-reported ear pain in 24 hours pre-enrolment.
- Had clinician diagnosis of AOM.
- The child is immunocompetent.
- A clinician is willing to use a NICE-recommended 'no' oral antibiotic prescribing strategy or a 'delayed' oral antibiotic prescribing strategy (as per NICE guidelines).
- A parent or legal guardian is able to give informed consent.

Q11

Children were excluded from the study if they were:

- severely ill
- unable to meet NICE delayed or no antibiotic for AOM criteria
- at a high risk of serious complications
- unfit to use topical ear drops
- allergic to the components of the active drop
- had an alternative cause for ear ache
- required antibiotics for a coexisting condition.

Q13

The IMP for this trial was a benzocaine-phenazone otic solution. This is an oil-based, combined local anaesthetic (benzocaine) and analgesic (phenazone, also known in the USA as antipyrine) ear drop. One ml contains 14 mg (1.4%) of benzocaine and 54 mg (5.4%) phenazone suspended in a glycerine-based

Q12

liquid along with a preservative (hydroxyquinolone sulphate). Despite an absence of published evidence of effectiveness, it is available as a pharmacy medicine in Australia and has been marketed since 1947 under Auralgan and other brand names. For this trial we intended to test Auralgan sold in 15-ml bottles. The placebo was glycerine (Albany Molecular Research Ltd, Glasgow, UK), with identical packaging to the active drops.

Randomisation was stratified by centre in blocks of 30 packs, each block having the packs arranged in a random and consecutively numbered sequence. The IMP supplier provided the pharmacy with medicine packs which had each been pre labelled with the patient identifier (ID) and medicine pack ID numbers. Each pack contained either two bottles of active medicine, two bottles of placebo medicine or no bottles but a non-medicinal item of comparable weight. Patients were enrolled by their general practitioner (GP) or research nurse who, at the stage of enrolment, was unaware of the contents of the next treatment pack in the sequence (maintaining allocation concealment). When the informed consent process was completed and signed, the trial pack was opened and allocation to active drops, placebo or no drops was confirmed. It was not clear if antibiotic prescribing decisions were made before or after opening the pack.

Q14

During the 8 days following randomisation, parents completed a daily questionnaire that asked about antibiotic use, ear pain on days 1 and 2, analgesic (e.g. ibuprofen or paracetamol) consumption, symptom presence and severity (e.g. episodes of crying, disturbed sleep and fever) adverse events, new or worsening symptoms (only asked on last day), satisfaction with, and opinion of, treatment allocation and future intention to use drops, costs, preference-based quality of life using CHU-9D, child's quality of life using the OMQ-14.

Q15

The net incremental costs to the NHS and society of using active ear drops compared with usual care (no drops) in the short (8 days) and medium term (3 months) was assessed. NHS resource use (e.g. antibiotic or analgesic use, GP visits) and societal costs (school/nursery absences, parent lost productivity and other family expenses) were reported by parents in the 8-day questionnaire. Medium-term NHS resource use was collated from a review of the child's GP records.

All parents agreeing to participate were asked, at the time of consent, if they were willing to be contacted about taking part in a telephone interview. In-depth telephone interviews were conducted with parents 14 days after randomisation. Lines of questioning focused on views and experiences of the disease, its diagnosis, treatment and recovery, information and support needs, and views and experiences of participation within the trial. Interviews also explored the potential implications of making the CEDAR drops available over the counter, which means that the costs will shift from the NHS to the individual. Health-care professionals were to be interviewed to explore their views and experiences of the trial, information and support needs, and their attitudes to the future implementation of treatments. A flexible interview topic guide was used to ensure that primary issues were covered during all interviews, but without dictating data collection. The interviewer used open-ended questioning techniques to elicit participants' experiences and views of key events and participants were asked to provide examples.

Based on existing literature, an antibiotic consumption rate of 80% was assumed for the usual treatment (no drop) group. To show an absolute 20% reduction in antibiotic consumption from a baseline of 80% (thought likely to have important effects on antimicrobial resistance), with 90% power at the 5% significance level, the trial would require 119 patients in each group. Allowing for a 20% loss to follow-up, the target sample size was adjusted to 149 in each group.

The primary outcome of antibiotic consumption was analysed using logistic regression, adjusting for whether or not the child had received a delayed antibiotic script at baseline. Secondary outcome measures were compared between the study groups using an appropriate regression model. Health economic analysis was undertaken primarily for intergroup (active ear drops vs. usual care) comparison of the NHS, family and societal cost per antibiotic consumption avoided during the AOM episode. The qualitative interview data were subjected to thematic analysis using an inductive approach to identify major themes.

Q16

Results

Owing to a delay in procurement of a suitable placebo, the study (especially the three-group study) was delayed and ultimately had to be closed prior to achieving recruitment targets and prior to collecting 3-month follow-up measures. A total of 74 (active drops, $n = 38$; and usual care, $n = 36$) patients were recruited into the two-group study and 32 (active drops, $n = 12$; placebo drops, $n = 10$; and usual care, $n = 10$) were recruited into the three-group study between October 2016 and June 2017. Among patients allocated between anaesthetic–analgesic ear drops and usual care, the only apparent baseline difference was delayed antibiotic prescribing in 11% of the usual-care group and 31% of the active drop group. More differences were expected to occur by chance in the three-group study owing to the modest sample size; differences were apparent in gender, accompanying adult's age and employment status, living in an area of deprivation, breastfeeding status at 3 months, episodes of distress/crying and disturbed sleep.

Q17

In the two-group study, 1 out of 29 (3%) and 9 out of 30 (30%) children in the active drop and usual-care groups, respectively, consumed antibiotics. In the three-group study, the corresponding numbers were 0 out of 10 (0%) and 2 out of 8 (25%) children. Combining data from the two-group and three-group studies gives pooled estimates of the odds ratio, comparing active drops to usual care of 0.09 [unadjusted, 95% confidence interval (CI) 0.02 to 0.55; $p = 0.009$] and 0.15 (adjusted for prescription of delayed antibiotic at recruitment, 95% CI 0.03 to 0.87; $p = 0.035$).

Q18

Mean (standard deviation) parent-reported ear pain scores at day 2 were 3.10 (2.23), 2.14 (1.07) and 5.00 (1.73) in the active drops, placebo drops and usual-care groups of the three-group study, respectively. Compared with placebo drops ($n = 7$), slightly greater ear pain was apparent in the active drop group ($n = 10$; adjusted difference in means 0.67; 95% CI -1.44 to 2.79), although this difference could have arisen by chance.

There were no differences seen in the use of analgesic consumption or illness duration, but overall symptom burden was slightly reduced in the active group compared with both placebo and usual-care groups. Health economic analysis revealed a statistically significant intergroup difference in antibiotic costs of £0.38 ($p = 0.01$) but the overall health-care costs associated with the AOM were similar at £75.07 and £76.92 in the active and usual-care groups, respectively.

There was a single, unrelated, serious adverse event (breathing problems) in the usual-care group. We found no difference in reporting of adverse events between groups.

Three interviews were conducted with participating trial parents. Key findings include the following:

- Parents felt the trial was a good idea and were happy for their child to participate.
- Parents described that wanting to help relieve their child's ear pain was the main reason for consulting.
- Parents did not express any preconceptions about the need for antibiotics.
- Parents spoke positively about the trial drops and stated that they would be happy to purchase the drops over the counter from a pharmacy, provided that pharmacist advice was available.

Conclusions

This study has provided evidence that anaesthetic–analgesic ear drops significantly reduce antibiotic consumption in childhood otitis media. The key weakness of this study is the small sample size and the consequent low statistical power to detect a true effect of the intervention. The small sample size for both the quantitative and qualitative aspects of this study resulted from a much shorter recruitment period than was planned. Despite this, CEDAR provides evidence of a substantial treatment effect in reducing antibiotic consumption, possibly mediated by reduced antibiotic prescribing. The study was not able to establish if reduced antibiotic consumption was achieved by a reduction in ear pain. Early study closure also prevented qualitative interview completion and the collection of 3-month follow-up data. Finally, there was lower than predicted antibiotic consumption in all study groups, perhaps suggesting that the participating GPs and parents were more motivated than the norm to reduce antibiotic use.

The premise of the study was the importance of tackling antibiotic resistance by reducing unnecessary antibiotic use in AOM. This study suggests that substantial reduction in antibiotic use might be achieved in AOM-affected children by combining a no or delayed prescribing strategy with anaesthetic–analgesic ear drops. There were no adverse events in the active treatment group. Importantly, the parents interviewed expressed their willingness to obtain the drops over the counter, with pharmacist guidance. Replication in a study with larger sample size would allow more confidence in informing clinical guidelines with these findings, would ensure the safety of the intervention over a longer follow-up period and, by establishing the mechanism by which antibiotic use is reduced, would allow refinements to the intervention.

Trial registration

This trial is registered as ISRCTN09599764.

Funding

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research (NIHR). Alastair D Hay was funded by a NIHR Research Professorship (NIHR-RP-02-12-012).

Chapter 1 Introduction

Structure of this report

In this chapter, the rationale for reducing antibiotic prescriptions by treating ear pain in acute otitis media (AOM) with anaesthetic–analgesic is presented. *Chapter 2* describes the study population, gives details of the interventions being compared and the study design. *Chapter 3* presents the results of the study, followed by discussion and conclusions in *Chapter 4*.

Background

There is broad agreement that a high proportion of prescriptions for antibiotics are unjustified^{1,2} and likely to be harmful given the clear relationship between primary care prescribed antibiotics and bacterial resistance.³ Furthermore, resistant bacteria are transmitted to social contacts, which is a problem with young children who are unaware of hygiene conventions and who have high contact rates with other children, parents and grandparents.^{4,5}

In September 2013, the Department of Health and Social Care published the *UK Five Year Antimicrobial Resistance Strategy 2013 to 2018*,⁶ which calls for change in the understanding and response to antimicrobial resistance by the public, the NHS and the government in the UK. Its overarching goal is to slow the spread of antimicrobial resistance through three strategies: (1) improving the knowledge and understanding of antimicrobial resistance, (2) conserving and stewarding the effects of existing antibiotics and (3) stimulating the development of new antibiotics. Conserving and stewarding the effects of antibiotics can be achieved in five ways: (1) reducing the overall quantity of antibiotics prescribed and consumed, (2) when antibiotics are needed, promoting the use of narrow spectrum agents, (3) when antibiotics are in demand but are ineffective, providing alternatives, (4) reducing the transmission of antibiotic-resistant bacteria and (5) vaccinating against antibiotic-resistant bacteria.

Acute otitis media is a common, painful condition of childhood that has an impact on the family because of disrupted sleep and time off work and school. Primary care consultation and prescription of an antibiotic have been the mainstay of management; one UK study found that between 80% and 84% of children presenting to primary care with AOM were prescribed an antibiotic during the years 1995–2011.^{1,2} This is despite the available evidence of benefit being restricted to children < 2 years old with bilateral AOM and those with otorrhoea,⁷ leading National Institute for Health and Care Excellence (NICE) to conclude that these are the only children warranting a same-day full course of antibiotic treatment.⁸ For other children, the use of a ‘wait-and-see’ strategy, with or without a delayed prescription for an antibiotic, has been shown to be safe in terms of treatment failure and in the frequency of complications of AOM including mastoiditis.^{9,10}

Evidence of the effectiveness for alternatives to antibiotics is urgently needed to reduce the largely inappropriate reliance on antibiotics, and to relieve the most common and distressing symptoms of AOM. The results of the Children’s Ear Pain Study (CEDAR) are presented in this report, which investigated if anaesthetic ear drops are effective in reducing the consumption of antibiotics by children with AOM.

Literature review

Three previous trials have assessed the effectiveness of topical analgesia against placebo in relieving pain due to AOM.^{11–13} All were included in a Cochrane review (updated 2011) that concluded that ‘the

evidence from [these] RCTs is insufficient to know whether ear drops are effective'.¹⁴ In any case, those studies did not assess the impact of topical analgesia on antibiotic prescribing when used as an approach to the management of an episode of AOM, and so it is unknown whether or not parents will see topical analgesia as an effective and preferable alternative to antibiotics and, therefore, reduce unnecessary antibiotic use.

Auralgan™ drops have been used in Australia for > 40 years with little or no evidence of harm. Prior to commencing this study, as part of the trial risk assessment and because of the theoretical potential for induce methaemoglobinaemia, we undertook a search of the Australian Therapeutic Goods Administration Database of Adverse Event Notifications (DAEN) (www.tga.gov.au/database-adverse-event-notifications-daen). On 2 December 2015, the DAEN was searched for adverse event reports associated with Auralgan between 1 January 1971 and 19 August 2015. A total of 11 cases were reported, all of which appear to be minor adverse effects (some patients showed more than one adverse effect): ear pain (two cases), discomfort (two cases), pruritus (one case), hyperacusis (one case), hearing impaired (one case), eye pain (one case), tinnitus (one case), burning sensation (two cases), ear canal erythema (one case), accidental exposure and overdose by child (one case), deafness (two cases), depressed mood (one case). This suggests a low risk of adverse reactions to Auralgan ear drops. There is a further potential for adverse effects arising from reduced antibiotic prescribing to children with AOM. However, previous observational data suggest that the frequency of such adverse effects is likely to be extremely low.¹ Moreover, in a survey of Australian pharmacies undertaken as part of preparation for the trial, it was established that these drops are widely available over the counter and sometimes used to avoid the need for a GP consultation (unpublished survey data).

Q19

Q20

Study aim

The aim of the CEDAR trial is to investigate the clinical effectiveness and cost-effectiveness of benzocaine plus phenazone (active) ear drops compared with usual care (no drops) for reducing antibiotic consumption in children aged between 12 months and 10 years presenting to primary care with AOM.

Specific research questions

Following a presentation to primary care with AOM, and compared with usual care:

1. Do active drops lead to a lower proportion of children consuming antibiotics in the first 8 days?
2. Do active drops lead to reduced oral analgesic consumption in the first 8 days?
3. Do active drops provide superior pain relief in the first 24–36 hours?
4. Do active drops provide superior pain relief in the first 24 hours?
5. Do active drops alter the number of days before starting antibiotics in the first 7 days?
6. Do active drops reduce the overall symptom burden, including episodes of crying or distress, disturbed sleep, interference with normal activity, appetite and fever, in the first 7 days?
7. Do active drops alter overall illness duration?
8. What are the net incremental costs to the NHS and society in the short (7 days) and medium (3 months) term?
9. Are the net incremental costs of active ear drops justified by improved pain relief, symptom burden, antibiotic use or quality of life?

Further objectives were to use qualitative methods to investigate parents' and clinicians' views and experiences of AOM in children in the CEDAR trial, and to investigate the representativeness of the CEDAR trial sample by describing the presentation, management and outcome of children with AOM in primary care.

Chapter 2 Methods

Study design

The CEDAR trial was a multicentre randomised controlled trial (RCT) and the participating children were randomly allocated between three study groups: active treatment (benzocaine-based ear drops), placebo treatment (drops without the 'active' ingredient) and no drops (current standard care). Parents who did not want their children to take part in the trial but were willing to complete the study diary were offered enrolment in an observational cohort study (Figure 1).




FIGURE 1 The CEDAR trial three-group randomised study with observational cohort study. OCS, observational cohort study.

Recruitment sites and site training

General practitioners at primary care research network practices in Bristol, Cardiff and Southampton were invited to take part in the study.

Training was delivered to each clinician who was involved in the trial. The training provided an outline of all trial recruitment and baseline data collection procedures, including how to train parents in administering the ear drops (for parents of children allocated to one of the treatment groups) and completing the Symptom and Recovery Questionnaire. A clinician training log was maintained at sites and within the Trial Master File reflecting the staff who had been trained. Clinicians at all participating primary care sites were also offered ongoing support, recruitment advice and refresher training on request by the study team.

Participants and recruitment

Eligibility

Children were eligible if they met all the following criteria:

1. Aged ≥ 12 months and < 10 years.
2. Presenting within 1 week of suspected AOM onset (other preceding respiratory tract infection symptoms may be longer).
3. Parent/legal guardian available to give consent.
4. Parent-reported ear pain in 24 hours pre-enrolment (or parent-suspected ear pain if child is too young to report pain).
5. Clinician diagnosis of AOM.
6. Child is immunocompetent.

Q21

7. Clinician willing to use a NICE-recommended 'no' oral antibiotic prescribing strategy or a 'delayed' oral antibiotic prescribing strategy (as per NICE guidelines) for the AOM and other elements of the underlying acute respiratory tract infection. NICE recommends a 'no' or 'delayed' antibiotic prescribing strategy for most immune-competent children with AOM.
8. Parent able to give ear drops.
9. Parent willing in principle to use ear drops before oral antibiotics and to wait before giving delayed antibiotics as per NICE guidelines.
10. Parent able to report the child's ear pain.
11. Parent able and willing to complete daily Symptom and Recovery Questionnaire in the English language, and receive regular follow-up telephone calls, in the English language, today and every 2 or 3 days for up to 7 more days (or until child has been free of ear pain without medicines for 2 days running).

Children were not recruited if they matched any of the following exclusion criteria:

1. Child requires immediate hospitalisation.
2. Child requires same-day oral antibiotic treatment for AOM or other elements of the underlying acute respiratory tract infection (assess these children for observational study eligibility). NICE recommends same-day antibiotic treatment for:
 - i. child < 2 years with bilateral AOM
 - ii. otorrhoea (discharge from the ear)
 - iii. child systemically very unwell or showing signs of respiratory distress (e.g. tachypnoea, hypoxia or recession)
 - iv. child has symptoms and signs suggestive of serious illness and/or complications (particularly mastoiditis)
 - v. child is at a high risk of serious complications because of pre-existing comorbidity. NICE guidelines recommend the following children are excluded:
 - child has significant heart, lung, renal, liver or neuromuscular disease (defined for the purposes of this study as requiring ongoing inpatient or outpatient care from specialist teams)
 - child has immunosuppression (defined for the purposes of this study as a formal diagnosis of immunosuppression)
 - child has cystic fibrosis
 - child born prematurely (defined as for the purposes of this study as born < 34 weeks and presenting within the first year of life)
 - note: children with other conditions who are at higher risk of AOM (e.g. Down's syndrome, cleft palate) may take part if the responsible clinician feels that they meet the inclusion criteria above.
- vi. Child requires same-day oral antibiotics for another (non AOM) infection or topical antibiotic ear drops.
- vii. Child is currently receiving (or has received in the past 7 days) oral or ear drop (to the AOM ear) antibiotic treatment.
- viii. Suspected or confirmed perforation (owing to theoretical and unconfirmed risk of ototoxicity from active drops) or grommets still in situ.
- ix. Known sensitivity to trial medicine (Auralgan) or to its ingredients (benzocaine, phenazone, glycerine, hydroxyquinoline sulphate) or similar substances (e.g. other ester-type anaesthetics such as procaine, tetracaine).
- x. Known porphyria or haemoglobinopathy or glucose-6-phosphate dehydrogenase (G6PD) deficiency or methaemoglobinaemia.
- xi. Known family history of G6PD deficiency (noting that G6PD deficiency is more common in African, Asian and Mediterranean populations).
- xii. Current use of sulphonamides or antimalarials or hyaluronidase or St John's wort.

Q22

Q23

- xiii. Child needs to continue taking other medicinal products containing benzocaine.
- xiv. Child has proven alternative source(s) of pain other than and more severe than the ear symptoms with which they are presenting.
- xv. Otitoscopic appearances (as ascertained by clinician, when possible) consistent with observed fever (i.e. likely non-specific viral illness only, for example with just a slightly perfused or pink drum only).
- xvi. Child has normal ear on examination.
- xvii. Child has otitis externa, or other disorder of the outer ear or tympanic membrane for which the CEDAR trial ear drops should not be prescribed, in the AOM ear.
- xviii. Child has a hearing aid and parent feels hearing aid should remain in place in the AOM ear.
- xix. Symptoms (i.e. hearing loss and longer duration of illness) more suggestive of a diagnosis of otitis media with effusion (glue ear).
- xx. Child has previously taken part in the CEDAR trial.
- xxi. Child has taken part in any research involving medicines within the last 90 days, or any other AOM-related research within the last 30 days.

Changes to the eligibility criteria

The team investigated methaemoglobinaemia and its association with benzocaine consumption in children. Although the potential risk was deemed very small, a decision was made to exclude children under the age of 12 months, rather than 6 months as previously planned.

Interventions

The investigational medicinal product (IMP) for this trial was a benzocaine and phenazone otic solution. This is an oil-based, combined local anaesthetic (benzocaine) and analgesic (phenazone) ear drop. One ml contains 14 mg (1.4%) of benzocaine and 54 mg (5.4%) phenazone suspended in a glycerine-based liquid along with a preservative (hydroxyquinolone sulphate). Despite an absence of published evidence of effectiveness, it is available as a pharmacy medicine in Australia and New Zealand, and has been marketed since 1947 under Auralgan and other brand names. For this trial we intended to test Auralgan sold in 15-ml bottles.

The placebo was glycerine, with packaging as close in appearance as possible to that used for the active drops.

Outcomes

Primary outcome

Proportion of children who consumed antibiotics by day eight: parents of the children recruited into the CEDAR trial were asked to complete an 8-day Symptom and Recovery Questionnaire which asked, on each day, whether or not they had given the child antibiotics. Completion of all eight questions was required to create an overall consumed/did not consume binary variable.

Secondary outcomes


Ear pain score on day 2

The 8-day Symptom and Recovery Questionnaire also asked the parent to rate their child's ear pain on a scale of 0–10 (*Figure 2*). Although active drops should have an almost immediate effect, the evening of day 2 was chosen as the time at which the drops had enough time to ease ear pain if they were going to. Active and placebo drops were compared with see whether or not the active ingredient provided relief over and above the soothing effects of the oily liquid in which they are contained. Placebo drops were also compared with usual care to test whether or not the oily liquid itself was more effective than nothing at all. The key secondary outcome tested the difference in ear pain scores between active and placebo drops whereas an additional secondary outcome tested difference in ear pain between placebo and usual-care groups.

2. CHILD'S EAR PAIN SCORE DAY 2

Please score your overall impression of your child's ear pain **in the evening** of Day X, thinking how they have been on average **over the last 24 hours**, using the scale below in the same way as you scored the pain on previous days. If your child is aged 5-10, please score the ear pain **before** your child fills in their symptom chart for the day.

a) Please score your overall impression of your child's ear pain **over the last 24 hours** using the scale and write the score in the boxes below:



Score (0-10)

FIGURE 2 Parent-completed assessment of pain.

Ear pain score on day 1

Another objective was to see whether or not the drops had an immediate effect on pain; therefore, parents were asked to score their child's ear pain 1 hour after giving the first dose of ear drops. Active and placebo drops were compared to see whether or not the active ingredient provided relief over and above the soothing effects of the oily liquid in which they are contained. Pain scores were on a scale of 0–10. This was then compared between active and placebo groups.

Analgesic consumption

On each day of the symptom diary, parents were asked whether or not they had given their child any analgesics (e.g. ibuprofen or paracetamol). The number of doses was also recorded. A binary variable was created to identify children who had received analgesics on any of the first 8 days versus children who had not received any oral analgesics during any of the first 8 days; this measure was not derived for children with any missing oral analgesic data during the first 8 days. This measure was then compared between active and placebo groups.

Number of days before taking antibiotics

The number of days before taking antibiotics was obtained from the child's symptom questionnaire. This was then compared between active and placebo groups, and between active and usual-care groups.

Mean overall symptom severity on days 1–4

Parents were asked to complete questions concerning other symptoms such as episodes of crying, disturbed sleep and fever in their symptom diaries. Symptoms were rated on a scale of 0 (no problem) to 6 (extremely bad). All symptom scores were combined for each patient per day before calculating the area under the curve for days 1 to 8. This was then compared between active and placebo groups, and between active and usual-care groups.

Overall illness duration

The number of days until the parent rated score was 0 for 2 consecutive days was calculated for all children. This was then compared between active and placebo groups, and between active and usual-care groups.

Adverse events

Details of serious adverse events were collected, and the trial team notified immediately, using adverse event forms. Parents were also asked on the last day of their questionnaire whether their child had experienced any new or worsening symptoms during the trial.

Patient satisfaction

Parents were asked about their satisfaction with, and opinion of, treatment allocation and future intention to use drops (with/without prior GP consultation if drops were to become available over the counter) 8 days post randomisation.

NHS and societal costs

The net incremental costs to the NHS and society of using active ear drops compared with no drops (usual care) in the short (8 days) and medium term (3 months). NHS resource use (e.g. antibiotic or analgesic use, GP visits) and societal costs (school/nursery absences, parent lost productivity and other family expenses) were reported by parents in the 8-day questionnaire. Medium-term NHS resource use was collated from a review of the child's GP records.

Child's quality of life

Preference-based quality of child life was measured (baseline, 24–36 hours, 8 days and 3 months post randomisation) using the CHU-9D.¹⁵ The CHU-9D is not designed for, or validated for preschool children; therefore, this measure was only used in children aged ≥ 5 years. The OMQ-14¹⁶ was given at baseline and 3 months post randomisation for children aged ≥ 2 years (clinical report form and postal/online questionnaire at 3 months).

Sample size

Previous studies have suggested that 80–90% of children presenting to UK GPs with AOM received a prescription for an antibiotic.^{17,18} It has also been argued that a 20% change in consumption could have important effects on antimicrobial resistance.³ The number of children needed in each group (active ear drops and usual care) to demonstrate a true 20% fall in antibiotic consumption, from 80–90% in the control group to 60–70% in the active ear drop group, with 90% power and two-sided significance level of 0.05, ranged from 92 to 119 children. Using the more conservative estimate of 119 children, and making provision for 20% attrition, this gave a target sample size of 149 children per group.

Our key secondary outcome was pain on day 2, measured using a validated 0 to 10 numerical rating scale. Based on the findings of a previous study using this measure,¹⁹ and the opinions of our patient and public involvement group, it was felt that a reduction in pain of 1 point was a clinically important difference. With 90% power and $\alpha = 0.05$, we can detect a true mean difference of one [standard deviation (SD) 2.5] in pain score between the active and placebo ear drop groups can be detected with 90% of power at the two-sided significance level of 0.05, with 133 children per group. Accommodating 20% attrition, and assuming equal numbers in the three groups, we needed 167 children per group (more than for the primary outcome) and 501 children in total.

Random allocation

Each pack contained either two bottles of active medicine, two bottles of placebo medicine, or no bottles. Randomisation was stratified by centre in blocks of 30 packs, each block having the packs arranged in a random and consecutively numbered sequence. The Bristol Randomised Trials Collaboration provided the pharmaceutical supplier with a set of patient IDs, which were allocated to a pack according to the sequence for the current block for a centre. The supplier provided the pharmacy with medicine packs that had each been pre-labelled with the patient ID and medicine pack ID numbers.

Patients were enrolled by their GP or research nurse who, at the stage of enrolment, was unaware of the contents of the next treatment pack in the sequence (allocation concealment). When the informed consent process was completed and signed, the trial pack was opened and allocation to drops (active or placebo) or not was confirmed.

Blinding

Although parents were aware if their child had been allocated to the usual-care group, if they received drops they were not aware if they had received active or placebo drops. An unblinded comparison of parents provided with ear drops and those allocated to usual care was the appropriate approach to establishing if the provision of ear drops would reduce antibiotic consumption in children with ear pain due to AOM. All parents, researchers and clinicians were blinded to the treatment allocation between active and inactive drops as far as possible. The statistician had unblinded access to the data in February 2017, to report to the Data Monitoring Committee, when approximately 50 patients had been recruited.

Statistical methods

The main statistical analyses were prespecified in a statistical analysis plan. The final version of the statistical analysis plan was signed off on 19 September 2017. A confidential interim analysis was completed in February 2017 for the Data Monitoring Committee. Final data analysis started in October 2017 and finished in January 2018. Stata® 14.2 (StataCorp LP, College Station, TX, USA) was used for all statistical analyses.

Statistical primary analysis

All parents of recruited children were asked to complete an 8-day symptom diary that asked, on each day, 'Did your child take any antibiotics by mouth today?'. The primary analysis was conducted using the modified intention-to-treat (ITT) approach, including only children with full 8-day data for this question. We used logistic regression to compare children who had taken antibiotics on any of the 8 days with those who had taken no antibiotics during the first 8 days.

H_0 : the proportion of children consuming antibiotics is the same in both groups.

H_1 : the proportion of children consuming antibiotics is different between the groups.

The primary hypothesis was whether or not active drops reduced the proportion of children consuming antibiotics compared with usual care (no drops).

Statistical secondary analyses

As for the primary analysis, secondary outcome measures were compared between the study groups using an appropriate regression model. When data were skewed, the square root transformation used to obtain a difference in means. Descriptive statistics were presented for adverse events and patient satisfaction.

Sensitivity analyses

We prespecified a per-protocol analysis, as a sensitivity analysis, including participants in the full analysis set who were deemed to have no major protocol violations that could interfere with the objectives of the study. Compliance per day was measured only for days when the pain score was ≥ 1 . Any volume of liquid used on that day was considered compliant. Therefore, if there was patient-reported pain for 5 out of 8 days, and drops were used for all five of the days with pain, then we classed this as 100% compliance. We carried out a per-protocol analysis for which we removed any patients from the active group who were considered non-compliant. This was prespecified as those taking their trial medication on $< 50\%$ of the days that they reported pain.

In a further sensitivity analysis, those who were lost to follow-up in the active drops group were assumed to have taken antibiotics and those in the usual-care group were assumed not to have done so.

As a post hoc sensitivity analysis we removed patients who were found to be ineligible after having been recruited to the study and allocated to a group.

Subgroup analyses

The following subgroups of children were prespecified for investigation of any treatment effect differences on the primary outcome measure. A treatment subgroup interaction term was added to the respective regression model:

- Prior duration of illness (≤ 72 hours vs. > 72 hours)
- Visibility of the ear drum (yes or no)
- Extent of AOM (unilateral or bilateral)
- Whether they had been given a delayed antibiotic script.

Recurrence of AOM was listed in the analysis plan in error (as it is a measure of outcome); therefore, this subgroup analysis did not go ahead.

Exploratory analyses

Exploratory analyses were used to help us contextualise our main findings, by investigating the effects of antibiotics and analgesics on pain.

Health economic methods

The prespecified economic analysis consisted of a cost-effectiveness analysis and cost-consequence study. As antimicrobial resistance is such an important concern²⁰, our primary economic analysis was a cost-effectiveness analysis with antibiotic use as a proxy for this outcome. The economic case for or against the active drops is most likely to hinge on externalities, i.e. antibiotic use and resistance, in the population, rather than purely within trial estimates of costs and quality of life. The cost-consequence study (including quality of life) was a secondary economic analysis.

The primary comparison was the NHS and societal cost per antibiotic consumption avoided during the acute episode between those children receiving active ear drops and those receiving usual care. The active treatment (Auralgan) is currently not in the *British National Formulary* (BNF)²² or available in UK pharmacies and, therefore, there is no national unit cost available. Auralgan is available to purchase over the counter in Australian pharmacies. The median retail cost for a 15-ml bottle in December 2017 at 10 online Australian pharmacies was AU\$10.99, equivalent to approximately £5.20 Great British pounds when converted using 2016 Organisation for Economic Co-operation and Development purchasing power parity statistics²¹ or £10.40 retail cost for the two 15-ml bottles given to each participant in the active drops group of the trial. We assumed that if used in routine UK clinical practice, Auralgan would be prescribed by a GP and, therefore, the cost would be borne by the NHS rather than by the family. For many medicines, the NHS drug tariff paid to pharmacies is much lower than the retail cost. For example, for 120 mg/5 ml of oral suspension paracetamol the drug tariff cost is approximately one-third of the retail cost. Therefore, in our primary analysis we assumed that the cost to the NHS of two 15-ml bottles of Auralgan would be £3.54 and we conducted a sensitivity analysis assuming the NHS would pay the retail cost of £10.40.

- Q24** The incremental NHS treatment costs during the first 8 days after randomisation were ascertained from the SRQ questionnaire and valued using national unit costs^{22,23} using 2016/17 values, when available. Parents recorded whether or not their child received an antibiotic on each day while symptoms persisted. We assumed that the antibiotic prescribed was 250 mg of amoxicillin, three times a day (age 1–4 years) or 500 mg three times a day (age ≥ 5 years) for 7 days. Using the NHS drug tariff price,²⁴ this equates to a cost of £1.17 (age 1–4 years) or £2.34 (\geq age 5 years) per antibiotic prescription.

Q25

Parents also recorded daily use of ibuprofen or paracetamol during the first 8 days. When use was reported, we assumed this was prescribed (i.e. it was a cost borne by the NHS) and that age-appropriate doses were given. For example, based on national drug tariff prices,²⁴ the cost of a 2-year old child taking 100 mg/5 ml of ibuprofen three times a day for a total of 20 doses was £1.28.

For Auralgan and antibiotics, we assumed that the whole cost would be incurred no matter how frequently parents administered the medicine (i.e. the remaining medication would be disposed of after the acute episode rather than reused during later episodes). For paracetamol and ibuprofen, we assumed that the cost of the medication would be proportional to the number of times it was administered (i.e. the remaining medication would be stored and reused during later episodes).

On the eighth day after randomisation, parents were asked to report any further consultations with their GP, the NHS 111 telephone service or hospital ambulatory care relating to their child's ear symptoms. Parent productivity costs were measured on the eight-day questionnaire and valued using average earnings. Bootstrapping was used to calculate confidence intervals (CIs) around the point estimate of the incremental cost-effectiveness ratio and cost-effectiveness acceptability curves.

In the secondary economic analysis, we prespecified a cost-consequence study tabulating 3-month treatment costs, including data from the 3-month GP note review, alongside other important outcomes including 24- to 36-hour ear pain relief, overall symptom burden, acute illness duration and CHU-9D utility scores. At the request of the funder, the GP note review was not conducted; therefore, we did not estimate 3-month treatment costs and present only CHU-9D utility scores at 3 months.

Qualitative methods

To examine the views and experiences of AOM and its treatment, qualitative interviews were conducted with parents, and clinicians involved in the care of trial participants. The interview topic guide included the perceived effectiveness and acceptability of treatment, and exploration of any barriers to treatment uptake outside the trial.

Sampling

All parents agreeing to participate in the trial were asked, at the time of consent, if they were willing to be contacted about taking part in a telephone interview. From willing participants, a purposive sample was to be drawn in relation to (1) trial site (Bristol, Southampton, Cardiff), (2) trial group (active/placebo or usual care) and (3) sociodemographic factors including child's age, ethnicity and socioeconomic status (with participants being selected from areas of high and low social economic deprivation, based on an *Index of Multiple Deprivation* score).²⁵ Health-care professionals (GP's and nurse practitioners) involved in the trial were to be purposively sampled in relation to (1) trial site and (2) length of time since qualification. Samples sizes would be determined by the need to achieve data saturation, such that no new themes emerged by the end of data collection.²⁶ Interviews were to be analysed in batches, and sampling to continue until no new themes emerged.

Interview conduct

In-depth telephone interviews were conducted with parents 14 days after randomisation. Lines of questioning within interviews focused on views and experiences of (1) the disease (2) its diagnosis, (3) treatment and recovery, (4) information and support needs and (5) views and experiences of participation within the trial. Interviews also explored the potential implications of making the CEDAR drops available over the counter, where the costs will shift from the NHS to the individual. Health-care professionals were to be interviewed to explore their views and experiences of the trial, information and support needs and their attitudes to the future implementation of treatments.

All interviews were conducted by telephone. At interview, participants were asked to give verbal consent, following which a flexible interview topic guide was used to ensure that primary issues were covered during all interviews, but without dictating data collection. This allowed participants to introduce unanticipated issues. The interviewer (CC) used open-ended questioning techniques to elicit participants' experiences and views of key events and participants were asked to provide examples. Interviews were recorded using a

digital voice recorder, transcribed using a professional transcription service and anonymised to protect confidentiality. Parents who took part in interviews received a £10 high street voucher.

Qualitative data analysis

Interview transcripts were checked for accuracy and then imported into NVivo 11 (QSR International, Warrington, UK) qualitative analysis software to aid management and indexing of data. Analysis began after the first interview and was ongoing and iterative. Earlier data were to inform further data collection; for instance, analytic insights from data gathered in earlier interviews would help identify any changes that needed to be made to the topic guide during later interviews. Thematic analysis²⁷ utilising a data-driven inductive approach²⁸ was used to identify and analyse patterns and themes of salience to participants and across the dataset using constant comparison techniques.^{29,30} First transcripts were read several times, to gain familiarisation with the data and initial ideas. Transcripts were then examined line by line with inductive codes being assigned to data segments that provided insight to participants' views and understandings. An initial coding frame was developed, and newer data were compared with previous data, and then with the properties of emerging categories that contain the main themes. The process of constant comparison allowed the generation of new themes, reclassification of themes and incorporation of themes within other themes, with the coding frame being modified as analysis developed. A subset of transcripts was to be independently double-coded by other members of the research team and compared, and discrepancies discussed and resolved to achieve a coding consensus and to maximise rigour.

Chapter 3 Results

Study progress

Study recruitment had been planned to take place between June 2015 and June 2017. Owing to a delay in the supply of a suitable placebo, recruitment began in October 2016 across 27 GP practices with a two-group internal pilot phase. Children were randomly allocated to the active treatment group or the usual-care group. The protocol change necessary for the two-group trial (protocol version 1.4) received approval from the ethics committee in August 2016 (NHS HRA reference 15/SC/0376). When the placebo became available in March 2017, the three-group study began recruiting across 35 GP practices. Although the two- and three-group designs ran concurrently for 3 months, the two studies did not run at the same time within any given practice. Owing to the late start of the three-group trial, the observational cohort for parents who did not want their children to take part in that trial but were willing to complete the study diary (see *Figure 1*) was not initiated. Recruitment to the trial closed as planned in June 2017, a recruitment period of 9 months having been achieved rather than the planned 24 months.

In April 2017, a Data Monitoring Committee meeting was held, which highlighted that antibiotic prescribing rates were much lower than assumed in all study groups combined, and consequently the sample size target would not provide 90% statistical power. This may in part have been due to children requiring immediate antibiotics, and so ineligible for the trial, accounting for a bigger than assumed proportion of those prescribed antibiotics in the studies used to inform the sample size calculation. Following this finding, the Trial Management Group, along with the Trial Steering Committee, jointly agreed that the data collected should serve as internal pilot data (i.e. the data would be included in the primary analysis) and an application made to extend the study to allow further recruitment with a revised exclusion criterion relating to antibiotic prescribing.

In Autumn 2017, this application to extend the study was declined by the funders, and the study was required to close by the 31 December 2017, several months earlier than originally planned. Owing to this, no 3-month reviews of primary care records were conducted, and so planned analyses relying on those reviews were not possible. The following presentation of results has adhered as closely as possible to the prespecified statistical analysis plan, including an amendment written as part of the study close-down plan, which adapts the original plan to data available from the internal pilot and full three-group stages.

Recruitment and completion of follow-up assessments

Seventy-four children were recruited during the two-group internal pilot, which ran from October 2016 to the end of April 2017, in 27 GP practices situated in all three centres. Thirty-two children were recruited to the three-group study, which ran from March 2017 to June 2017, in 35 GP practices in Bristol and Southampton. All 106 patients were recruited by 17 GPs, 18 nurses and 3 other health-care professionals, with each recruiting between 1 and 19 children. Our interim recruitment target at the end of June was 150 participants. After initially recruiting to target, recruitment fell short of the June target in part because of the time taken to switch practices from the two-group to the three-group trial, and in part because of the limited supply of treatment packs (see *Appendix 1* for the chart used to monitor recruitment).

Figure 3 shows the stages of the trial and the different levels of drop out that led to the final analysis sample. Overall, five patients randomised into the trial were found to be ineligible post randomisation. For three of these patients (two active two-group patients and one usual-care two-group patient), this was discovered shortly after randomisation and the patients were advised to return the drops and not complete the diary. For the other two of these patients, this was only noticed after follow-up had been completed.




FIGURE 3 The CEDAR trial CONSORT (Consolidated Standards of Reporting Trials) flow chart. a, Been using Otomize drops, temporary resident so clinician decided not to recruit, previously taken part in the CEDAR trial, grommets, history of bloody discharge, dental issue causing ear pain, patient seen at branch surgery and unable to come to main surgery for appointment; b, child not happy about taking part, parent did not want to risk getting placebo, parent did not want child to participate; c, child too unwell (clinician's view), risk of complications due to pre-existing comorbidities, right ear otitis externa, child too old, no reason stated; d, child too unwell (clinician's view), child not happy about taking part, parent did not have time for recruitment, no reason listed; e, recruitment to the two-group pilot ran from October 2016 to the end of April 2017 (in 27 sites) while recruitment to the three-group pilot ran from March 2017 to June 2017 (in 35 sites); 12 sites recruiting to the three-group pilot were previously involved in the two-group pilot. Although the two-group and three-group trials ran concurrently between March 2017 and June 2017, the two trials did not run at the same time within a given site; f, one patient who completed follow-up was later found to be ineligible (bilateral AOM and < 2 years); g, one patient who completed follow-up was later found to be ineligible (otorrhoea in right ear).

Q26

Q27

Given that our analysis was on an ITT basis, they were included in all analyses but excluded in a sensitivity analysis.³¹ Further detail of the availability of data on the two key outcomes of antibiotic use over eight days and pain reported are given in *Table 1*.

Q30 **Baseline data**

A total of 106 patients were randomised to the CEDAR two- and three-group studies and baseline characteristics are reported in *Tables 2–5*, respectively. The team prespecified in the analysis plan that any baseline characteristics that differed by at least 10%/0.5 SDs would be adjusted for in a sensitivity analysis. However, as the study recruited only one-fifth of the target sample size, the criterion was increased to 20%/0.75 SDs to counteract the increased chance of finding an imbalance.

In the two-group study, the only measure to have a difference, exceeding the prespecified criterion of 20% or 0.75 SDs, was receipt of a delayed prescription for an antibiotic (see *Table 3*). Those prescriptions should have been issued, and recorded, prior to randomisation, and so it should not be the case that allocation to study group influenced antibiotic prescription, although we are unable to confirm this for sure.

Prior to analysis, the criterion for imbalance for the three-group study was increased to 30%/1 SD to counteract the increased chance of finding an imbalance given the small sample size. Variables that exceeded this criterion were gender, accompanying adult's age and employment status, living in an area of deprivation, breastfeeding status at 3 months (see *Table 4*), episodes of distress/crying, and disturbed sleep (see *Table 5*).

Q28 **TABLE 1** Further details on data available for antibiotic consumption and pain outcome measures

Outcome measure	Active drops	Placebo drops	Usual care	<i>p</i> -value ^a
Two-group study, <i>n</i> (%)				
Number randomised	38		36	
Found to be ineligible	1 (3)		1 (3)	0.74
Withdrew from study	2 (5)		2 (6)	0.67
Lost to follow-up	6 (16)		5 (14)	0.54
8 days antibiotic data	29 (76)		30 (83)	0.32
Pain data on days 1 and 2	32 (84)		30 (83)	0.58
Three-group study, <i>n</i> (%)				
Number randomised	12	10	10	
Found to be ineligible	1 (8)	0	0	
Withdrew from study	0	0	0	
Lost to follow-up	1 (8)	3 (30)	1 (10)	0.48
8 days antibiotic data	10 (83)	7 (70)	8 (80)	0.87
Pain data on days 1 and 2	10 (83)	7 (70)	9 (90)	0.63

Q29

TABLE 2 Baseline characteristics by allocated group, two-group study

Characteristic	Active drops (<i>N</i> = 38)		Usual care (<i>N</i> = 36)	
	<i>N</i>	Mean (SD) or <i>n</i> (%)	<i>N</i>	Mean (SD) or <i>n</i> (%)
Centre				
Bristol	38	23 (61%)	36	23 (64%)
Cardiff	38	5 (13%)	36	4 (11%)
Southampton	38	10 (26%)	36	9 (25%)
Child's demographics				
Gender: male	38	18 (47%)	36	16 (44%)
Age (years)	38	4.6 (2.5)	36	4.6 (2.5)
Aged ≥ 5 years	38	17 (45%)	36	14 (39%)
White ethnicity	34	33 (97%)	31	31 (100%)
Living in an area of deprivation ^a	37	3 (8%)	35	3 (9%)
Exposure to potential risk factors				
Smokers in household	34	2 (6%)	31	1 (3%)
Additional children in household	34	22 (65%)	31	21 (68%)
Breastfed at 3 months	34	14 (41%)	31	9 (29%)
Does the child wear a hearing aid	34	0 (0%)	31	0 (0%)
Flu vaccination in last 12 months	34	15 (44%)	31	16 (52%)
Accompanying adult demographics				
Mother attended with child	29	26 (90%)	28	25 (89%)
Accompanying adult's age (years)	29	35.0 (6.0)	28	36.4 (6.7)
Accompanying adult employed/full time education/retired	34	25 (74%)	31	26 (84%)
Accompanying adult a university graduate	29	11 (34%)	28	11 (39%)

Q31

a Index of Multiple Deprivation based on the children's home postcode at birth, categorised as those living in the top 20% of deprived areas in the UK (England's 2015 rank and Wales' 2014 rank).

TABLE 3 Clinical characteristics at presentation by allocated group, two-group study

Characteristic	Active drops (<i>N</i> = 38)		Usual care (<i>N</i> = 36)	
	<i>N</i>	Mean (SD) or <i>n</i> (%)	<i>N</i>	Mean (SD) or <i>n</i> (%)
Ear pain/medication				
Child ear pain score (1–10) ^a	14	6.0 (2.6)	15	6.1 (3.1)
Parent ear pain score (1–10)	38	6.9 (1.5)	36	6.3 (1.7)
Number of days in pain	38	2.7 (2.0)	36	2.5 (1.4)
Received painkillers today ^b	37	32 (86%)	34	25 (74%)

TABLE 3 Clinical characteristics at presentation by allocated group, two-group study (continued)

Characteristic	Active drops (N = 38)		Usual care (N = 36)	
	N	Mean (SD) or n (%)	N	Mean (SD) or n (%)
Symptoms (scale 0–6)				
Episodes of distress/crying	37	3.8 (1.5)	34	3.3 (1.3)
Disturbed sleep	37	4.1 (1.6)	34	3.7 (1.6)
Interference with normal activities	37	3.1 (1.5)	34	2.7 (1.5)
Eating/drinking less than normal	37	2.7 (1.7)	34	2.2 (1.6)
Fever	37	1.9 (1.7)	34	2.7 (1.7)
Hearing problems	37	1.2 (1.4)	34	1.4 (1.8)
Cough	37	2.5 (1.8)	34	1.8 (1.7)
Blocked/runny nose	37	2.3 (1.8)	34	2.1 (1.8)
Vomiting	37	0.5 (1.5)	34	0.4 (1.0)
Clinical examination				
AOM in both ears/bilateral	38	8 (22%)	36	5 (14%)
General health of child (0–10) ^c	38	3.6 (1.9)	36	3.3 (1.8)
Temperature	38	37.0 (0.6)	36	36.9 (0.7)
Given a delayed antibiotic	38	4 (11%)	36	11 (31%)

a Answered by those aged ≥ 5 years.

b Has your child received any painkilling medicine (e.g. paracetamol or ibuprofen) in the last 6 hours before being checked for trial suitability.

c From 0 (not at all unwell) to 10 (extremely unwell).

TABLE 4 Baseline characteristics by allocated group, three-group study

Characteristic	Active drops		Placebo drops		Usual care	
	N	Mean (SD) or n (%)	N	Mean (SD) or n (%)	N	Mean (SD) or n (%)
Centre						
Bristol		8 (67%)		8 (80%)		6 (60%)
Southampton		4 (33%)		2 (20%)		4 (40%)
Child's demographics						
Gender: male	12	11 (92%)	10	3 (30%)	10	5 (50%)
Age (years)	12	4.9 (2.5)	10	5.0 (1.9)	10	4.6 (2.9)
Aged ≥ 5 years	12	7 (58%)	10	5 (50%)	10	7 (70%)
White ethnicity	10	9 (90%)	7	6 (86%)	9	9 (100%)
Living in an area of deprivation ^a	11	2 (18%)	10	0 (0%)	10	4 (40%)
Exposure to potential risk factors						
Smokers in household	10	1 (10%)	7	1 (14%)	9	2 (22%)
Additional children in household	10	8 (80%)	7	4 (57%)	9	7 (78%)
Breastfed at 3 months	10	7 (70%)	7	4 (57%)	9	2 (22%)
Does the child wear a hearing aid	10	0 (0%)	7	0 (0%)	0	0 (0%)
Flu vaccination in last 12 months	10	4 (40%)	7	4 (57%)	9	4 (44%)

continued

TABLE 4 Baseline characteristics by allocated group, three-group study (continued)

Characteristic	Active drops		Placebo drops		Usual care	
	N	Mean (SD) or n (%)	N	Mean (SD) or n (%)	N	Mean (SD) or n (%)
Accompanying adult demographics						
Mother attended with child	9	9 (89%)	7	5 (71%)	8	8 (100%)
Accompanying adult's age (years)	9	38.7 (6.8)	7	37.6 (8.2)	8	31.5 (3.1)
Accompanying adult employed	10	7 (70%)	7	6 (86%)	9	3 (33%)
Accompanying adult a university graduate	9	3 (33%)	7	3 (43%)	8	3 (38%)

a Index of Multiple Deprivation based on the children's home postcode at birth, categorised as those living in the top 20% of deprived areas in the UK (England's 2015 rank and Wales's 2014 rank).

TABLE 5 Clinical characteristics at presentation by allocated group, three-group study

Characteristic	Active drops		Placebo drops		Usual care	
	N	Mean (SD) or n (%)	N	Mean (SD) or n (%)	N	Mean (SD) or n (%)
Ear pain/medication						
Child ear pain score (1–10) ^a	7	6.4 (2.3)	4	5.5 (3.0)	4	7.5 (2.5)
Parent ear pain score (1–10)	11	6.3 (1.8)	10	5.3 (1.3)	10	6.2 (2.2)
Number of days in pain	11	1.5 (0.9)	10	2.7 (1.5)	10	2.3 (1.8)
Received painkillers today ^b	11	7 (64%)	9	4 (44%)	10	7 (70%)
Symptoms (scale 0–6)						
Episodes of distress/crying	11	3.0 (1.7)	9	2.4 (1.3)	10	4.2 (1.7)
Disturbed sleep	11	2.9 (1.5)	9	2.7 (1.3)	10	4.2 (1.3)
Interference with normal activities	11	2.5 (1.8)	9	2.9 (1.5)	10	3.3 (1.3)
Eating/drinking less than normal	11	1.7 (1.6)	9	2.4 (1.8)	10	2.0 (1.7)
Fever	11	1.2 (1.6)	9	2.1 (1.5)	10	2.1 (1.9)
Hearing problems	11	1.4 (1.6)	9	1.0 (1.6)	10	0.7 (1.1)
Cough	11	1.0 (1.0)	9	2.2 (1.7)	10	1.5 (1.6)
Blocked/runny nose	11	1.8 (1.9)	9	1.7 (1.1)	10	2.9 (1.8)
Vomiting	11	0.2 (0.6)	9	0.4 (1.3)	10	0.5 (1.1)
Clinical examination						
AOM in both ears/bilateral	11	2 (18%)	10	4 (40%)	10	2 (20%)
General health of child (0–10) ^c	11	3.9 (1.7)	10	3.3 (1.5)	9	3.1 (1.2)
Temperature	11	37.1 (0.8)	10	37.5 (1.3)	9	37.1 (0.6)
Given a delayed antibiotic	11	3 (27%)	10	1 (10%)	10	3 (30%)

a Answered by those aged ≥ 5 .

b Has your child received any painkilling medicine, e.g. paracetamol or ibuprofen, in the last 6 hours before being checked for trial suitability.

c From 0 (not at all unwell) to 10 (extremely unwell).

Outcomes and estimation

Primary outcome: antibiotic consumption

The primary research hypothesis was to find whether or not active ear drops would reduce antibiotic consumption compared with usual care. In the two-group study, 30% of patients in the usual-care group consumed antibiotics by day 8 compared with only 3% in the active drops group (*Table 6*). Results from the three-group study, although on a much smaller sample size, were very similar: 25% in the usual-care group versus 0% in the active drops group. These two results were combined in a meta-analysis (with a continuity correction of 0.4444 to allow calculation of an odds ratio in the three-group study). The combined odds ratio supports the conclusion that with 95% confidence, the crude odds of taking antibiotics is between 45% and 98% lower in the active drops group compared with usual care (see *Table 6*). After controlling for the effect of administering a delayed antibiotic script at randomisation, the CI widens, weakening the evidence against the null hypothesis (see *Table 6*).

Receipt of a delayed antibiotic script was prespecified as a potential confounding variable in the statistical analysis plan; *Table 7* shows a stratified analysis investigating the impact that the delayed antibiotic script had on proportion of children consuming antibiotics. Overall, 47% (9/19) of those children given a delayed antibiotic script went on to consume an antibiotic, compared with 9% (6/65) of those not given a delayed antibiotic script. For the two-group trial, 70% (7/10) of children given a delayed antibiotic went on to consume antibiotics if they were in the usual-care group, compared with 0% (0/3) of the children in the active drops group.

Data from the three-group study were used to investigate whether or not active ear drops would reduce antibiotic consumption compared with placebo drops. A total of 43% (3/7) of patients in the placebo drops group consumed antibiotics by day 8 compared with 0% (0/10) in the active drops group. Using a Fishers exact test, there is moderate evidence to suggest that active drops reduce antibiotic consumption compared with placebo drops ($p = 0.051$).

TABLE 6 Primary analysis: antibiotic consumption, by group

Antibiotic consumption	Active drops, n/N (%)	Usual care, n/N (%)	OR (95% CI)	p-value	OR (95% CI) ^a	p-value ^a
Two-group	1/29 (3)	9/30 (30)	0.08 (0.01 to 0.71)	0.023	0.12 (0.01 to 1.18)	0.069
Three-group	0/10 (0)	2/8 (25)	0.11 (0.00 to 3.17) ^b	0.201	0.20 (0.01 to 3.49) ^b	0.270
Combined	1/39 (3)	11/38 (29)	0.09 (0.02 to 0.55) ^c	0.009 ^c	0.15 (0.03 to 0.87) ^d	0.035 ^d

OR, odds ratio.

a Adjusted for delayed antibiotic script, missing for one patient in the three-group trial.

b Continuity correction of 0.4444.

c Pooled estimate using the inverse variance method, $I^2 = 0.0\%$.

d Pooled estimate using the inverse variance method, $I^2 = 29.1\%$.

TABLE 7 The impact of giving a delayed antibiotic script on consumption of antibiotics, by group

Antibiotic consumption	Two-group study, n/N (%)		Three-group pilot, n/N (%)		
	Active drops	Usual care	Active drops	Placebo drops	Usual care
Prescribed delayed antibiotic	0/3 (0)	7/10 (70)	0/3 (0)	0/0 (0)	2/3 (67)
No prescribed delayed antibiotic	1/26 (4)	2/20 (10)	0/7 (0)	3/7 (43)	0/5 (0)

Key secondary outcome: ear pain on day 2

Parent-reported pain scores at day 2, in the three-group study, are presented in *Table 8*. There was no evidence to suggest that pain was reduced in active compared with placebo drops groups. Unadjusted and adjusted results were in favour of the placebo drops with pain scores observed to be, on average, 0.96 points higher in the active group. There was evidence to suggest that pain was reduced in the placebo drops compared with usual-care groups. Unadjusted and adjusted results were in favour of the placebo drops with pain scores on average 2.86 points higher in the usual-care group (see *Table 8*), and the 95% CI excluded the prespecified 1-point minimum clinically important difference.

We carried out a post hoc secondary analysis comparing ear pain between the active and usual-care groups. There was evidence (*Table 9*) to suggest that active ear drops reduced ear pain, which was strengthened after adjusting for baseline ear pain (at consultation). After adjustment, the combined mean difference was almost 2 points on the 0- to 6-point scale, with the 95% CI almost excluding the minimum clinically important difference and close to the effect of the placebo drops reported in *Table 8*.

Secondary outcome: ear pain on day 1

There was no evidence to suggest that pain was reduced in active compared with placebo drops groups on day 1 (*Table 10*).

TABLE 8 Key secondary analysis: ear pain score on day 2, by group

Group	Ear pain, mean (SD); n	Mean difference (95% CI)	p-value	Mean difference (95% CI) ^a	p-value ^a
Placebo drops	2.14 (1.07); 7	Comparison			
Active drops	3.10 (2.23); 10	0.96 (−0.99 to 2.91)	0.312	0.67 (−1.44 to 2.79)	0.506
Usual care	5.00 (1.73); 9	2.86 (1.25 to 4.46)	0.002	2.86 (1.13 to 4.60)	0.003

a Adjusted for the parent reported pain score at consultation.

TABLE 9 Exploratory analysis: ear pain on day 2, by group

Group	Active drops, mean (SD); n	Usual care, mean (SD); n	Mean difference (95% CI)	p-value	Mean difference (95% CI) ^{a,b}	p-value ^{a,b}
Two-group	2.81 (2.32); 32	4.43 (2.54); 30	−1.62 (−2.86 to −0.39)	0.011	−2.01 (−3.23 to −0.78)	0.002
Three-group	3.10 (2.23); 10	5.00 (1.73); 9	−1.90 (−3.85 to 0.05)	0.056	−1.93 (−3.92 to 0.05)	0.055
Pooled	2.88 (2.28); 42	4.56 (2.37); 39	−1.70 (−2.74 to −0.66)	0.001	−1.99 (−3.01 to −0.95) ^b	< 0.001 ^b

a Adjusted for the parent-reported pain score at consultation.
b Pooled estimate using the inverse variance method, $I^2 = 0.0\%$; $p = 0.884$.

TABLE 10 Secondary analysis: ear pain on day one (approximately 1 hour after administering the drops), by group

Group	Active drops, mean (SD); n	Placebo drops, mean (SD); n	Mean difference (95% CI)	p-value	Mean difference (95% CI) ^a	p-value ^a
Ear pain	2.70 (1.16); 10	3.42 (1.62); 7	−0.73 (−2.16 to 0.70)	0.295	−0.74 (−2.32 to 0.85)	0.338

a Adjusted for the parent-reported pain score at consultation.

Combining the two- and three-group study data, *Figure 4* shows the average daily pain scores for each of the three groups. Over the 8 days, lower levels of pain were reported by the active drop and placebo drop groups.

Secondary outcome: oral analgesic consumption

Oral analgesic consumption was high, with 88% of children taking paracetamol or ibuprofen during the first 8 days after consultation. There was no evidence to suggest a difference in oral analgesic consumption between those taking active and placebo ear drops (*Table 11*).

During the recruitment process, parents were asked if their child had received any painkilling medicine prior to the recruitment consultation and 56 out of 79 (71%) participants said that they had. All 56 of these children then went on to take analgesics during the study. Out of the 23 that did not give their child painkilling medicine before taking part in the study, five continued to not use analgesics during the trial (active drops, $n = 2$; placebo, $n = 1$; and usual care, $n = 2$).

Considering the number of doses of oral analgesic that the children were receiving over the 8 days, there were no clear differences in the two-group study (*Figure 5*). In the three-group study, children allocated to the active drops appeared to take fewer doses than their placebo and usual-care counterparts (see *Figure 5*). However, these observed differences were consistent with chance (*Table 12*).

Patients were also asked if there were any other painkilling remedies that they had given their child. Only one additional treatment was reported for one child: Otrivine nasal drops over 2 days.

Q33




FIGURE 4 Mean pain scores by day and group, combining the two- and three-group children and including only those with full 8 days' data on ear pain.

TABLE 11 Secondary analysis: analgesic consumption, by group

Group	Active drops, n/N (%)	Placebo drops, n/N (%)	OR (95% CI)	p-value	OR (95% CI) ^a	p-value ^a
Analgesic consumption	8/9 (89)	6/7 (86)	1.33 (0.07 to 25.91)	0.849	1.21 (0.04 to 34.00)	0.911
Ibuprofen	4/9 (44)	3/7 (43)				
Paracetamol	6/9 (67)	6/7 (86)				

OR, odds ratio.

^a Adjusted for the parent-reported pain score at consultation.




FIGURE 5 Analgesic consumption up to day 8 for the two- and three-group studies. The box and whisker plots show the distributions of analgesic consumption. The box represents the IQR, the line within the box is the median, the upper and lower ‘whiskers’ are defined as the 75th percentile + 1.5 × IQR and the 25th percentile – 1.5 × IQR, respectively. The dots outside these ‘whiskers’ are the outliers observed in the data. IQR, interquartile range.

TABLE 12 Secondary analysis: number of doses of oral analgesic, by group


Group	Active, median (IQR); n	Placebo, median (IQR); n	Difference in means ^a	p-value ^a
Number of doses	2.0 (1.0–5.0); 9	6.5 (2.0–9.0); 6	–0.54 (–1.86 to 0.787)	0.397

IQR, interquartile range.
 a Calculated using the square root of the number of doses.

Q32

Secondary outcome: overall symptom burden

For a first exploration of symptom burden, each child’s scores (high scores indicate greater severity, maximum score of 36 on each day) on each of the symptom measures was added together to give a total for each of the 8 days following recruitment. An ‘area under the curve’ approach (broadly equivalent to taking the average score for each child over the 8 days) was taken, with the resulting scores being positively skewed (Figure 6) and so were transformed (by taking the square root) to allow analysis with linear regression.



Q34 **FIGURE 6** Mean symptom burden in the two-group [(a) and (b)] and three-group studies [(c), (d) and (e)]. (continued)




FIGURE 6 Mean symptom burden in the two-group [(a) and (b)] and three-group studies [(c), (d) and (e)].

For both the two- and three-group studies, the active drops appeared to lead to a faster resolution of symptoms, and so a lower symptom burden over the 8 days (see *Figure 6*), with modest evidence in support of these differences (*Table 13*).

TABLE 13 Secondary analysis: overall symptom burden over 8 days, quantified as the area under the curve, by group

Group (study)	Symptom burden, median (IQR); <i>n</i>	Difference in means ^a	<i>p</i> -value ^a
Active drops (three-group)	15.8 (8.5–21.5); 10	Comparison	
Placebo drops (three-group)	24.5 (10.5–50.5); 7	1.81 (–0.28 to 3.90)	0.085
Usual care (three-group)	28.5 (14.0–42.0); 9	1.35 (–0.13 to 2.84)	0.072
Active drops (two-group)	11.5 (5.8–33.5); 32	Comparison	
Usual care (two-group)	30.3 (6.3–45.0); 28	1.14 (–0.20 to 2.49)	0.094

IQR, interquartile range.
^a Calculated using the square root of the area of the curve.

Secondary outcome: overall illness duration


Children in the active group appeared to be recovering at a faster rate than those in the usual-care group (Figure 7), but this difference was consistent with chance (Table 14). There was no evidence against the proportional hazards assumption.

Secondary outcome: time to antibiotic consumption

This measure was only reported for 15 children across the two studies, with no reports for some groups; consequently, the data are uninformative and not presented here.

Secondary outcome: adverse events

There was one serious adverse event experienced during the trial as a result of which a child was admitted to hospital due to breathing issues. The child was discharged from hospital the next day and the parent continued to complete the questionnaire. This child was allocated to the usual-care group, and so the event can be considered as unrelated to the ear drops.



Q35 **FIGURE 7** Kaplan Meier curve for the time to recovery from pain in the two-group trial. Time to recovery (score = 0).

TABLE 14 Overall duration of pain

Group (study)	Pain duration, median (IQR); <i>n</i>	Hazard ratio	<i>p</i> -value
Active drops (three-group)	3 (3–5); 10	Comparison	
Placebo drops (three-group)	2 (2–4); 7	1.70 (0.61 to 4.75)	0.31
Usual care (three-group)	3 (2–6); 9	0.94 (0.38 to 2.61)	0.90
Active drops (two-group)	3 (2–5); 34	Comparison	
Usual care (two-group)	4 (3–X ^a); 31	0.62 (0.34 to 1.11)	0.11

IQR, interquartile range.

^a Missing 75th percentile owing to large proportion of censoring at 8 days.

At the end of the week parents were asked to report any new or worsening symptoms, and six reports were made. For the active drops group, these included a head cold (moderate) and chickenpox (mild). Neither of these symptoms were thought to be related to the drops. For the usual-care group, there were reports of ringing in the ears (mild), a sore, snotty and bleeding nose (moderate), problem with balance (moderate) and itching around the neck (moderate); the last two were experienced by the same patient. No new or worsening symptoms were reported for the placebo drops group.

Secondary outcome: parent satisfaction

When parents were asked if they were satisfied with the trial ear drops, 93% (27/29) of parents receiving active drops in the two-group trial said that they were satisfied and 7% (2/29) of parents reported that they were neither satisfied nor dissatisfied. Parents of children allocated to active drops in the three-group trial reported 90% (9/10) satisfaction, with 10% (1/10) reporting that they were neither satisfied nor dissatisfied. Only 57% (4/7) of parents with children allocated to placebo drops reported satisfaction, with 29% (2/7) reporting that they were neither satisfied nor dissatisfied and 14% (1/7) reporting that they were not satisfied.

In the three-group trial, parents of children recruited to the active or placebo drops were asked on day 8 if they thought that their child was taking the painkilling ear drops. In the active group, 60% (6/10) thought that their child was taking the painkilling ear drops and in the placebo group, 29% (2/7) thought that they were.

When asked if they would use the drops if they were to be available over the counter, all parents in the two-group trial said 'Yes', with 69% in the active group saying that they would take them without GP advice compared with 50% in the usual-care group. Of the 26 children recruited in the three-group trial, two parents said that they would not use the drops if they became available; both were in the blinded placebo group. When asked what they would use in the future, 79% (23/29) of those in the active group of the two-group trial said just the trial drops, compared with 40% (4/10) of those active group patients in the three-group trial; these results are given in *Figure 8*. When comparing the answers to this question between those who gave their children antibiotics during the study and those who did not, it was found that those who gave antibiotics were more likely to say that they would use antibiotics again (20%, 3/15) than those who had not (3%, 2/69).




FIGURE 8 By trial group: what would you want to use for your child for a similar illness in the future?

Sensitivity analyses

Per-protocol analysis

The trial team, together with the Data Monitoring Committee, defined compliance as taking study medication on $\geq 50\%$ of the days that they reported pain. The per-protocol analysis excluded patients not achieving this level of compliance.

Overall, 78% of parents reported using the drops on all of the days that they reported pain. There was only one child who did not comply at least 50% of the time, and this was the one child in the active drops group (two-group study) who consumed antibiotics. When we repeat the analysis without this child, the evidence of reduced antibiotic use in the active drops group remains (Table 15).

Sensitivity analysis: missing data imputed under best- and worst-case scenarios

Twenty-two children withdrew or were lost to follow-up before completing 8 days of reporting, and their antibiotic consumption status was therefore unknown. For a best-case scenario, the 11 children in the active group were assumed to have completed the trial without taking antibiotics, and the 8 children in the usual-care group were assumed to have taken antibiotics at some point during the 8-day follow-up. For the worst-case scenario, the 11 children in the active group were assumed to have taken antibiotics and the 8 children in the active drops group were assumed to have completed follow-up without consuming antibiotics. These assumptions are at the two extremes and the results, as expected, show that the best-case scenario strengthens the evidence for reduced antibiotic use in the active drops group, whereas the worst-case scenario weakens the evidence such that a reduction in antibiotic use is no longer clearly apparent (Table 16).

TABLE 15 Sensitivity analysis: per-protocol analysis excluding from the two-group study, one child who did not meet the compliance criterion for the study medication – antibiotic consumption, by group

Group	Active drops, n/N (%)	Usual care, n/N (%)	OR (95% CI)	p-value
ITT analysis	1/29 (3)	9/30 (30)	0.08 (0.01 to 0.71)	0.023
Per-protocol analysis	0/28 (0)	9/30 (30)	0.04 (0.00 to 0.73) ^a	0.030 ^a

OR, odds ratio.
^a Calculated using a continuity correction of 0.4828.

TABLE 16 Sensitivity analysis with missing data imputed under best- and worst-case scenarios: antibiotic consumption, by group

Variable	Active drops, n/N (%)	Usual care, n/N (%)	OR (95% CI)	p-value
Best-case scenario				
Two-group trial	1/38 (3)	15/36 (42)	0.04 (0.00 to 0.31)	0.002
Three-group trial	0/12 (0)	4/10 (40)	0.05 (0.00 to 1.29) ^a	0.071 ^a
Worst-case scenario				
Two-group trial	10/38 (26)	9/36 (25)	1.07 (0.38 to 3.04)	0.897
Three-group trial	2/12 (17)	2/10 (20)	0.80 (0.09 to 7.00)	0.840

OR, odds ratio.
^a Calculated with a continuity correction of 0.4545.

Sensitivity analysis: exclusion of children found to be ineligible following allocation

The primary analysis was repeated without two children who were found to be ineligible only after data collection was complete, one child in the usual-care group of the two-group trial (who had bilateral AOM and was < 2 years old) and one child in the usual-care group of the three-group trial (who had otorrhoea in one ear). *Table 17* shows the results when these two children were removed from the analysis. After removing the two ineligible children, the evidence for a reduction in antibiotic use in the active drops group was strengthened slightly.

Exploratory analysis: reported pain by antibiotic use

For those with pain scores for all 8 days, children who took antibiotics ($n = 15$) appeared to have higher pain scores than those who did not take antibiotics ($n = 69$) during the study (*Figure 9*). Although the direction of cause and effect could not be established from these data, it is possible the use of antibiotics resulted from the higher pain.

Subgroup analyses

Q36 The evidence for subgroup effects is difficult to interpret in the context of low statistical power, which was the case for this study because of the modest sample size realised and the dimensions investigated having one subgroup much larger than the other. Consequently, the summary statistics are presented in *Table 18*.

TABLE 17 Sensitivity analysis with two children found to be ineligible removed: Antibiotic consumption, by group

Antibiotic consumption	Active drops, n/N (%)	Usual care, n/N (%)	OR (95% CI)	p-value
Two-group trial	1/29 (3)	9/29 (31)	0.08 (0.01 to 0.68)	0.021
Three-group trial	0/10 (0)	2/7 (29)	0.09 (0.00 to 2.84) ^a	0.171 ^a

OR, odds ratio.

^a Calculated with a continuity correction of 0.4118.




FIGURE 9 Mean pain scores by day and antibiotic consumption, combining the two- and three-group children and only including those with full 8-day data on ear pain.

TABLE 18 Subgroup variations in the effect of active drops vs. usual care on whether or not children consumed antibiotics

Subgroup	Active drops group		Usual-care group	
	N	Consumed antibiotics, n (%)	N	Consumed antibiotics, n (%)
Prior duration of illness				
≤ 72 hours	20	1 (5)	23	7 (30)
> 72 hours	9	0 (0)	7	2 (29)
Ear drum visible				
Yes	28	1 (4)	30	9 (30)
No	1	0 (0)	0	0 (0)
AOM ear(s)				
Unilateral	20	1 (5)	27	8 (30)
Bilateral	8	0 (0)	3	1 (33)
Antibiotic prescribing				
Delayed	3	0 (0)	10	7 (70)
None	26	1 (4)	20	2 (10)

Health economic results

Cost-effectiveness findings

The unit costs of resources are presented in *Table 19*. There were no substantial differences in the total costs of health care or parental time off work during days 1–8 (*Table 20*). The reduction in antibiotic use among participants allocated to receive active drops only leads to a very small reduction (£0.38) in antibiotic prescribing costs in the short term. A small number of children had repeat consultations with their GP, the NHS 111 telephone consultation service, or hospital ambulatory care services, but there was no difference in the cost of this care between groups. The mean number of parent/carer days off work was similar in the active drops (0.58 days) and usual-care (0.61 days) groups, but varied widely among respondents (range 0–6 days). Owing to the large variations in repeat consultations and time off work, the CI around the difference in total costs is wide and includes £0.

TABLE 19 Unit costs of resource valuation

Resource	Unit cost	Perspective	Source of cost
Active drops	£3.54 per 15-ml bottle	NHS	Online pharmacies
Antibiotic	£1.17 to £2.34 per prescription ^a	NHS	BNF ²²
Paracetamol	£0.24 to £0.87 per day ^a	NHS	BNF ²²
Ibuprofen	£0.19 to £0.58 per day ^a	NHS	BNF ²²
GP visit	£36.00	NHS	PSSRU ²³
NHS 111	£12.26	NHS	Evaluation of NHS 111 study report
Hospital related services	£199.00	NHS	PSSRU ²³
Time off work	£539.00 per week ^b	Societal	Office for National Statistics

PSSRU, Personal Social Services Research Unit.

a Depending on patient age.

b Median gross weekly earnings for full-time employees in the UK.

Q37

TABLE 20 Health care and time off work costs, days 1–8, by group

Resource	Active drops (<i>n</i> = 38), mean (SD)	Usual care (<i>n</i> = 37), mean (SD)	Mean difference (95% CI)	<i>p</i> -value
Active drops	£3.54 (0)	£0 (0)		
Antibiotics ^a	£0.06 (0.38)	£0.44 (0.80)	–£0.38 (–0.67 to –0.10)	0.01
Ibuprofen ^a	£0.44 (0.57)	£0.49 (0.62)	–£0.05 (–0.32 to 0.23)	0.73
Paracetamol ^a	£0.84 (0.90)	£1.17 (1.09)	–£0.32 (–0.78 to 0.13)	0.16
GP/NHS 111/ambulatory	£7.78 (40.66)	£9.27 (44.99)	–£1.49 (–21.21 to 18.23)	0.88
Time off work	£62.41 (75.74)	£65.55 (141.55)	–£3.14 (–55.20 to 48.91)	0.91
Total	£75.07 (99.47)	£76.92 (154.94)	–£1.85 (–61.61 to 57.91)	0.95

^a Dose adjusted for age.

Among the 75 children (active drops, *n* = 38; and usual care, *n* = 37) with complete data, our findings suggest that, from an NHS and societal perspective, active drops have the potential to both save money (£75.07 active drops; £76.92 usual care) and reduce antibiotic prescriptions (2.6% active drops; 27.0% usual care). Restricting the analysis to NHS costs (£12.66 active drops; £11.36 usual care) leads to an estimated cost of £5.19 per antibiotic prescription avoided, although this is associated with a high degree of uncertainty [95% CI lower limit (cost saving) undefined to upper limit £110]. The estimate is also sensitive to the unit cost of Auralgan; in a sensitivity analysis, assuming the NHS pays the approximate retail cost of £10.40, the cost per antibiotic avoided increased to £33.43.

Other outcomes

Children in both the active drops and the usual-care groups of the trial had improvements in health-related quality of life, measured by the CHU-9D, at 2 days after randomisation and further improvements were observed by day 8 (*Table 21*). As this questionnaire was only completed for children aged ≥ 5 years, the sample size is small. However, there is weak evidence that CHU-9D scores were higher (better) among children in the active drops group at 8 days. There was no difference in the mean number of days off school or preschool childcare (*Table 22*).

TABLE 21 The CHU-9D scores, by group

Group	Active drops, mean (SD); <i>n</i>	Usual care, mean (SD); <i>n</i>	Mean difference (95% CI)	<i>p</i> -value
Baseline	0.696 (0.121); 21	0.657 (0.148); 19	0.039 (–0.047 to 0.125)	0.367
Day 2	0.829 (0.146); 17	0.807 (0.154); 15	0.023 (–0.086 to 0.131)	0.672
Day 8	0.983 (0.030); 21	0.923 (0.109); 15	0.060 (0.010 to 0.110)	0.021

TABLE 22 Days off school or preschool childcare, by group

Group	Active drops, mean (SD); <i>n</i>	Usual care, mean (SD); <i>n</i>	Mean difference (95% CI)	<i>p</i> -value
Number of days	0.95 (0.92); 39	0.91 (1.29); 38	0.04 (–0.47 to 0.55)	0.873

Qualitative data results

Number and characteristics of parents

Three parents were interviewed, all of whom had taken part in the three-group trial. *Table 23* displays characteristics of the parents and their children, including the trial participant child.

Owing to the primary aim of the qualitative evaluation (examining parents' views and experiences of active, placebo and usual-care groups of the trial), interviews did not proceed until the three-group trial started. Six trial parents were contacted to take part in the qualitative interview; one did not respond, two agreed but could not conduct the interview within the study time-period, and three agreed and took part in an interview. Owing to limited number of interviews, data saturation was not reached.

Themes developed from the analysis are described below with the use of verbatim quotes.

Views and experiences of trial

Parents spoke positively about the trial, saying they thought it was a good idea. All the parents were pleased to be part of the trial and welcomed being invited to take part:

It sounded great and actually . . . it's such a great idea.

PA01

I was quite open to it.

PA02

I think that the trial was good.

PA03

Parents demonstrated a good understanding of the aims of the trial:

Well I guess it was to test this local, local anaesthetic stuff on kids, um to see if it helped um kids that regularly suffer from ear pain, um whether it just you know to sort of um, kind of um avoid using antibiotics in the future.

PA03

TABLE 23 Interviewee characteristics

Parent	PA01	PA02	PA03
Number of children	3	1	3
Age range of children (years)	2–11	7	3–6
Age of participating child (years)	2	7	3
Previous history of AOM	Siblings and study child	Study child	Siblings
Active or placebo drops	Active	Placebo	Placebo
Index of multiple deprivation decile ^a	4	7	8

^a One being least deprived and 10 most deprived.

When deciding to participate in the trial perceived safety of the medicine was important to the parents as was the strength of the parent's faith and trust in doctors and 'scientists' (PA02). Although safety was a concern, information provided within the information sheet and by practice staff during discussions at the point of recruitment, about established safety of use of the treatment, calmed any fears. Parents also felt comforted by having choice and control over whether or not the drops were administered, and when:

I think it you know they [drops] were proven to help I was told in Australia and I thought well if they're available elsewhere . . . and they're safe, I'm quite happy. My boy was quite happy . . . to do it, so yea I was quite happy.

PA02

I thought it [the CEDAR trial] was good . . . and I always think it's as long as it's not, you know like it's a safe trial then I'm perfectly happy with that yeah.

PA03

I mean like I think that the trial was good, in that you know it did mention that if you don't want to take the ear drops, then you can just put zero on that day . . . that was kind of a very positive kind of thing for me because you know I wouldn't, I didn't feel the pressure to have to like to do it if it was really just she was really hard to hold down or something, I'd just like right that's that done and not to have to have committed to doing it for five or six or seven, do you know what I mean like kind of kept, that was kind of a choice which I kind of yeah appreciated.

PA03

Parents also felt that, as the drops were being externally applied, as opposed to an oral medication, any risk was lowered, and it was safer for the child to use. This added to their comfort for their child being involved in the trial:

I guess because it wasn't like they were taking medicine orally, they were kind of, it was sort of an external thing that made me think that it was probably safer . . . but it they were giving me something, a trial that was a medicine you consumed, then maybe I'd be a bit more concerned about that.

PA03

Parents felt that they had sufficient information to enable them and their child to take part in the trial. Information provided through the information sheet and by the study team was clear and well received. Parents appreciated they could contact the study team with any queries. One parent used this resource to check whether they needed to continue with the drops when they felt that they did not need to any more:

It [study information] was fairly straightforward really, it just – it's quite – it was pretty self-explanatory . . . The only thing was I checked um about like how long to use them once he's got better, if you think – once you felt they'd got better . . . she [research nurse] was really good and she just messaged me back and just said that – carry on using it probably for like a couple of days after, like you would do with anything really, you know.

PA01

Parents interviewed did not use the online video that was available either because they felt that they did not need it as they already had sufficient information or did not have the time. The length of time and detail provided by the GP was important to parents and welcomed:

He [GP] was really good and really thorough about everything really . . . He went through it all of it actually . . . I think we were in there for ages, bless him, it made him very late . . . but he was really good and went through everything and checked, like went through it all with me.

PA01

Reasons for and experiences of consulting

Parents all consulted the GP because of their child being upset and in pain. One parent commented that because the child had a history of previous serious ear infection resulting in hospitalisation, she wanted 'piece of mind' (PA01). Parents had no expectations of the consultation other than the doctor would check the ear(s) and there would be discussion about any treatment. The main concern was to ease the child's pain, whether by use of antibiotics, as in the past, or by other means:

Really like that if it was an ear infection and it, um – that he would get antibiotics possibly, if that was right – it's really hard 'cause there's no – I wouldn't say I'd go for antibiotics. But it's a discussion you would have with the doctor.

PA01

Thing was he was in pain, I just wanted him not to be in pain you know.

PA02

There's nothing worse than earache is there in kids?

PA02

Parents did not express an expectation of antibiotics from the consultation even if their child had used them in the past and were aware of the issue of antibiotic resistance:

You don't just want to give them antibiotics because they get resist – you know, then the resistance come up and stuff.

PA01

I didn't really [expect antibiotics], I don't really, I'm not overly keen on the idea of constantly giving kids antibiotics so you know as long as I don't think that there's any danger of the infection getting worse, then I'd prefer to let yeah, I'd prefer to them to sort of recover by themselves yeah.

PA03

Parents were aware of attempts to decrease antibiotic use and embraced advice provided by the GP concerning their use. GPs had explained, within the initial trial consultation, that the type of infection being experienced would clear up on its own and that antibiotics may be of little use. They felt this was a discussion that needed to happen between themselves and the doctor and that they would be happy with what the doctor recommended:

I wouldn't always say I'd go for antibiotics. But it's a discussion that you would have, I guess, with the doctor and see actually knowing his history that possibly antibiotics might be the right course. But if it's not that bad.

PA01

They [drops] help with pain with earache because if it's a viral earache then antibiotics don't necessarily work and the earache will go away on its own.

PA02

Well the doctor then, he told my husband that they were trying to not use antibiotics anymore and to leave it to clear up itself . . . I was happy with that to be honest . . . I mean I'd usually just take the doctor's advice and go with what they think is best, so on that account I was like right if they think it's going to clear up without antibiotics, that's fine.

PA03

However, being able to have a delayed antibiotics prescription meant that they felt reassured when given the drops in case the child's condition worsened. Parents did not use this prescription as they felt administering the trial drops was sufficient:

He [the GP] put my mind a bit more at ease because he gave me the delayed prescription . . . Because that was my only concern, that actually sometimes with [child's name] with his ear infections, they go from nothing to sort of like really bad, that we could get him a prescription without having to go back to the doctor if needed.

PA01

Views and experience of treatments

Q38

Pain relief for the child was important to the parents and was discussed most when exploring experience of using the drops. All parents believed that the drops that they had received had relieved pain levels within the first day and parents (including those who had received the placebo drops) reported reduced use of other forms of pain relief, for example, Calpol®. When asked whether they thought they had the active or the placebo drops, all parents felt that, because of the quick reduction in pain and not using additional pain relief, they had the active drops:

Obviously it was uncomfortable 'cause he didn't really like the drops being put in. But there wasn't a lot of pain, he didn't seem in pain with it and we didn't need to use much Calpol . . . it seemed to clear up quite quickly.

PA01

But he did say, he said his ear felt I don't know after about twenty minutes, it wasn't as painful as what it was before he had the drops . . . whereas he'd had an ear infection, earache before, it was a constant pain. And I hadn't been giving him Calpol, so I couldn't say that was taking the pain away.

PA02

It became apparent she was fine, like it got a bit, it became apparent that her ear wasn't hurting as much, she was like after you know a couple of days you could touch her ear without her complaining whereas before you couldn't even touch her without her crying.

PA03

Some parents discussed difficulties administering the drops as children were young and did not like the drops, or that parents had problems with the size of the bottles or drops:

The actual droplet thing was quite big for his ear . . . I think if it was a different bottle with a different, much smaller nozzle . . . it would have been a bit easier, because they were quite gloopy the drops were. So, I think if you could have got them in, the droplet was just a bit too fat, do you know what I mean?

PA02

Well it was fine, if I could get it into her ear, to begin with it was quite hard because she's only 3, she didn't, she doesn't like taking any type of medication or put cream on even you know, she's awkward with everything, so I had to you know we had to kind of hold her in position to get the ear drops in her ear . . . so that was quite awkward to be honest, I know they said you take up to 12 doses a day or something, but we could barely get in that many to begin with because of just the fight and stuff.

PA03

Parents compared the use of the drops with previous experiences of antibiotics and felt the drops were beneficial and would be happy to use for pain relief:

With the drops he appeared that the pain subsided whereas with antibiotics it takes a couple of days for it to start kicking in, so your topping them up with you know Calpol.

PA02

Yea I probably would [use drops] because you know if the doctor's saying to me you know if he has antibiotics, it's only going to take a day off the pain, you know if he is going to be pain free for just one less day . . . instead of pumping, instead of putting antibiotics in, if I could put just a painkiller and it would take the pain away . . . if the infection if going to clear up on its own anyway, I think it would be good to have a painkiller for him . . . to take the pain away.

PA02

Parents with the confidence that the benzocaine/phenazone drops had reduced pain in their children, would be happy to buy the drops from pharmacy (over the counter) rather than consult the GP. This was on the premise that a pharmacist would be available for advice and information:

You know you're giving it to a child, I think a little bit of advice from the pharmacist, how many times you can give it in a day and you know if the pain doesn't go away within so many days you know contact your doctor sort of thing.

PA02

I'd probably like to ask the pharmacist that you know what they thought, and you know if they knew about the product and everything, it would just be sort of how to use it, you know not to overdose on it, just kind of basic information you get on most medicines.

PA03

Chapter 4 Discussion

Summary of main findings

Despite the CEDAR trial falling short of its sample size target, and demonstrating a lower than expected antibiotic consumption rate, the results provide evidence of a reduction in antibiotic consumption with the use of anaesthetic–analgesic ear drops compared with children who were not provided with ear drops.

The primary analysis (active drops vs. usual care) showed modest evidence of a difference between groups when combining the results of the two- and three-group studies, with 11 out of 38 (29%) children in the usual-care group consuming antibiotics compared with 1 out of 39 (3%) children in the anaesthetic–analgesic drops group. This represents an 87% reduction in the odds of consuming antibiotics (odds ratio 0.13, 95% CI 0.01 to 1.13). If this reflects a true effect of the ear drops, the most likely explanation for reduced antibiotic consumption is reduced pain. However, secondary analyses showed that both glycerol and active drops to be superior to no drops for pain relief at day 2. The former could be explained by the placebo effect, or a soothing anti-inflammatory effect of glycerol. Secondary outcome measures provided modest evidence of reductions in oral analgesic consumption, symptom burden and illness duration in the active drops group compared with children allocated to the usual care group.

Q39

Our economic analyses demonstrated that the use of active drops is unlikely to reduce medication costs in the short term, primarily because antibiotics are cheap. The more substantial economic benefits are likely to come in the longer term, via reduced antimicrobial resistance. Nevertheless, the ‘cost per antibiotic avoided’ of active drops is low and if parental productivity costs are included in the analysis, it may even save money. Weak evidence was found that active drops improved health-related quality-of-life scores, measured by the CHU-9D at 8 days.

Interviews conducted with three participating parents revealed their views and experiences of AOM, its treatment and the CEDAR trial. The study aim was viewed positively by parents, who felt the treatment of pain to reduce the use of antibiotics was a good idea, and were happy for their child to participate. Parents’ main reason for taking their child to the doctor was because their child was upset and in pain and they wanted pain relief for their child. Parents did not express any preconceptions of whether or not the child should receive antibiotics, and were happy to discuss treatment options with the doctor. Parents spoke positively about the trial drops and all believed that they reduced pain in the child, although this was also the case for parents whose children received placebo drops. Parents stated that they would be happy to purchase the drops over the counter from a pharmacy, provided that pharmacist advice was available.

Strengths and weaknesses

The CEDAR trial was a pragmatic RCT conducted in UK primary care practices; allocation was concealed during recruitment and around 80% of parents provided full data on their child’s antibiotic consumption during the key 8-day follow-up period. However, the study was subject to a number of limitations.

The clear weaknesses of the CEDAR trial were the small sample size achieved (particularly with the planned three-group study), not being able to collect data at the planned 3-month follow-up point and not being able to commence recruitment in emergency departments as planned. Although comparisons of the raw data suggest a substantial treatment effect on antibiotic consumption, the results need to be interpreted with caution as estimates are imprecise, and we are not able to confirm the probable mechanism through reduced pain. This weakness is likely to be purely one of low statistical power; although the study did close

early, this is unlikely to have caused bias as early closure did not curtail the planned recruitment period, and was a decision of the funder who was unaware of the findings of the confidential interim analysis (although they had been made aware of the lower than expected antibiotic prescription rate across the three study groups combined). The lack of data at the 3-month follow-up means that the safety of the intervention in the period immediately after the infection, and the incidence of recurrent infection remain unknown.

We observed a greater proportion of children in the usual-care group than in the drops groups who received a delayed prescription for an antibiotic. We had intended for children to receive these prescriptions prior to being allocated to a study group, although we cannot guarantee that this always occurred and, in hindsight, whether or not the child had received a delayed prescription should have been included in the information provided when logging the child into the study, in preparation for allocation to a study group. Those children provided with a delayed prescription were more likely to consume antibiotics during the 8-day follow-up; our prespecified primary analysis attempted to control any confounding through this route. Of the small number of children in one of the drops groups who received a delayed prescription, none subsequently consumed antibiotics, which suggested that if receipt of a delayed prescription been equally low in the usual-care group, then this may have reduced antibiotic consumption in that group and hence reduced the difference in antibiotic consumption between study groups. However, taking a different view, although the intention had been to standardise antibiotic prescribing across the study groups, what actually happened in the trial would be closer to routine clinical practice in which GPs might prescribe fewer antibiotics if they can provide anaesthetic–analgesic ear drops instead, with the lower prescription rate resulting in lower antibiotic consumption.

In fact, antibiotic consumption was already lower than anticipated in the usual-care group, potentially owing to overcautious exclusion of children considered to need immediate antibiotics, less use of delayed prescriptions by participating GPs who are perhaps already keen to reduce antibiotic consumption, or due to informed consent procedures including the study rationale, which would have given parents the chance to opt out if they were keen to use antibiotics (the planned but unrealised observational cohort would have addressed this), or may have convinced some parents of the unsuitability of antibiotics for the treatment of AOM ear pain.

The larger number of participating children were recruited to the two-group study, which did not include the placebo drops group, and so could not provide reliable evidence that the anaesthetic–analgesic drops were reducing antibiotic consumption through a painkilling mechanism. However, despite the modest sample size realised, the study does provide weak evidence that parents of children presenting to primary care with ear pain due to AOM find ear drops to be an acceptable treatment and are consequently less likely to use antibiotics. It seems unlikely that a different pattern of results would have been observed had children in the drops groups been more often provided with a delayed prescription for antibiotics, and indeed the study shows that parents of children in the drops group found it acceptable not to receive such a delayed prescription.

From the perspective of the economic analysis, as Auralgan is not in the BNF,²² it is currently unclear how much the NHS would pay for it if GPs were to prescribe it. Plausible assumptions have been made based on drug prices in other high-income countries and potential NHS discounts. However, if the actual procurement price were higher, the intervention would be less cost-effective than we have estimated. Owing to falling short of the recruitment target, the evidence of a reduction in health care use up to 8 days was very weak, and with the review of medical records not going ahead, we were unable to evaluate whether or not the possible reduction in health care use might have been amplified over a 3-month period.

Strengths of the qualitative study are that it included parents who took part in the trial and were therefore able to provide views and experiences from those directly involved. Reported themes were present across all interviews and, therefore, strengthening their standing. All parents had previous experience of children with AOM and treatment and were therefore well placed to comment on whether or not the treatment was

acceptable and whether or not they believed it worked or not. The main limitation is the small number of interviews conducted. Although more were planned, only three interviews with trial parents were able to be conducted within the timeframe of the three-group trial. This does provide useful insight into how parents experienced the trial and using the trial drops. However, caution needs to be exercised when taking findings forward. Views were only captured from those who agreed and continued to participate in the trial. Further interviews need to be conducted with a larger number of parents to determine whether or not findings continue to be prevalent and important. Further issues including divergent views and experiences may also be uncovered. As the sample was small, it was not possible to utilise a maximum variation approach and parents with different characteristics need to also be interviewed, for example, socioeconomic backgrounds, child age, trial centre and trial group. Owing to the delay with the trial it was also not possible to capture views and experiences of health-care professionals. Therefore, important insights into how the people directly involved in the care of the children and who were key to successful trial implementation were not gleaned. Future research needs to capture the views and experiences of health-care professionals from a range of trial sites.

Comparison with other literature

No new randomised studies of anaesthetic–analgesic ear drops have been published since the last Cochrane review in 2011. The three previous studies have assessed the effectiveness of topical analgesia against placebo in relieving pain due to AOM;^{11–13} all were included in the Cochrane review (updated 2011), which concluded that ‘the evidence from [these] RCTs is insufficient to know whether ear drops are effective’.¹⁴ These studies address the efficacy of drops for pain and not the impact on case management with antibiotics; none of the trials included an economic evaluation. That said, pain relief is important to parents and this emerged in the qualitative interviews completed for this study. In a post hoc and unblinded comparison of ear pain between this study’s active and usual-care groups, there was moderate evidence to suggest that active ear drops reduced ear pain, which was strengthened after adjusting for baseline ear pain (at consultation). After adjustment, the combined mean difference was almost 2 points on the 0- to 6-point scale. In the analysis of pain relief following first instillation of drops in the small sample of 17 patients, there was no evidence to suggest that pain was reduced in active compared with placebo drops groups. However, both unadjusted and adjusted results were in favour of the active drops; those in the active groups had pain scores that were, on average, 0.73 points lower than the placebo group. Thus, despite the small sample size, the present study may make a further contribution to the Cochrane review.

There is a well-recognised variation in prescribing rates for otitis media, the median rate being 60% while in the highest decile of prescribing practices the figure is 90%.¹ A previous study in AOM investigated consumption,¹⁹ finding 24% of children consumed antibiotics following a delayed prescription compared with 33% in this usual-care group.

Our analyses suggest that anaesthetic–analgesic drops might increase medication costs during the acute episode. However, the wider societal costs of antimicrobial resistance were not quantified here. A literature review concluded that current estimates of the costs of resistance are likely to be underestimates and that an accurate forecast of costs may not be possible.²⁰ A recent trial evaluating the use of antibiotics in lower respiratory tract infections demonstrated that strategies to avoid antibiotic use become dramatically more cost-effective once the costs of resistance are included in the estimate.³²

Q40 Implications for policy, clinical practice and research

Tackling antibiotic resistance is an international priority and reducing unnecessary antibiotic use for self-limiting illness is one potential mechanism to address this. This study suggests that substantial reduction in antibiotic use might be achieved in AOM in children by combining a no or delayed prescribing strategy with anaesthetic–analgesic ear drops.

A benefit of the analgesic effect of the active drops remains unproven when compared with placebo, although both active and glycerol drops may have important pain-relieving properties. Further research is needed to establish if effects are mediated by the active ingredients, or could be achieved using a non-pharmacologically active oil.

Conclusion

This study has provided evidence that anaesthetic–analgesic ear drops result in a substantial reduction in antibiotic consumption in children presenting to primary care with AOM. The small number of children allocated to the placebo drops group was insufficient to establish whether or not the anaesthetic–analgesic ear drops reduced pain. Replication of these findings in a larger study would give greater confidence for informing clinical guidelines, would establish the safety of the intervention beyond the first 8 days and, if the mechanism of action can be established, may allow refinements to the intervention.

Acknowledgements

Q41 The CEDAR trial was designed and delivered in collaboration with the Bristol Randomised Trials Collaboration, a UK Clinical Research Collaboration Registered Clinical Trials Unit in receipt of National Institute for Health Research (NIHR) Clinical Trials Unit support funding.

The study sponsor was the University of Bristol, and we would particularly like to acknowledge the support of Birgit Whitman. We would like to thank the independent members of our oversight committees:

Trial Steering Committee – Jonathan Mant, Cambridge University, UK (chairperson); Kay Wang, Oxford University, UK; Alan Smyth, Nottingham University, UK; and Victoria Wilson, patient and public involvement member.

Data Monitoring Committee – Toby Prevost, Imperial College London, UK (chairperson); Christian Mallen, Keele University, UK; and Alecia Nickless, Oxford University, UK.

We would like to acknowledge the essential contributions made to the CEDAR trial by the following administrators at Bristol: Annie Sadoo, Kate Rowley, Penny Seume; Cardiff: Catherine Aymar; and Southampton: Oyinkan Alli-Balogen.

Study data were collected and managed using REDCap (Research Electronic Data Capture) tools (University of Colorado, Denver, CO, USA) hosted at the University of Bristol. REDCap is a secure, web-based application designed to support data capture for research studies, providing (1) an intuitive interface for validated data entry, (2) audit trails for tracking data manipulation and export procedures, (3) automated export procedures for seamless data downloads to common statistical packages and (4) procedures for importing data from external sources.

Q42 Funding history

The CEDAR trial was funded by the NIHR Health Technology Assessment programme. The project start date was 1 January 2015 and the planned study end date was 31 March 2018.

The project closed early, on 31 December 2017, as required by the funders. Issues were encountered with a lengthy delay to the IMP supply. Although the IMP supplier was identified through a competitive procurement process, the supplier failed to deliver the active drops and placebo in line with expected and revised timeframes. There were particular problems with the production of the matched placebo and the ability of the supplier to source materials to replicate the active drops. This contributed to the early closure of this important trial.

Q43 Contributions of authors

Alastair D Hay (University of Bristol) was the chief investigator and study management group member, and contributed to the primary care expertise, study design, protocol development, trial monitoring, writing and approval of final report.

Harriet Downing (University of Bristol) was the trial manager and study management group member, and contributed to the protocol development and trial monitoring.

Nick A Francis (Cardiff University) was the principal investigator for Cardiff Centre and study management group member, and contributed to the primary care expertise, protocol development, trial monitoring, writing and approval of final report.

Grace J Young (University of Bristol) was the study statistician, and contributed to the statistical analysis, reporting to the data monitoring committee, writing and approval of final report.

Clare Clement (University of Bristol) was the qualitative researcher, and contributed to the qualitative interviews and analysis, writing and approval of final report.

Sue D Harris (University of Bristol) was the study nurse and study management group member, and contributed to the primary care expertise and approval of final report.

Aideen Ahern (University of Bristol) was the health economics researcher, and contributed to the health economics analysis and writing and approval of final report.

Behnaz Schofield (Cardiff University) was a study management group member, and contributed to the primary care expertise, protocol development, trial monitoring and approval of final report.

Tammy E Thomas (Southampton University) was a study management group member, and contributed to the primary care expertise, protocol development, trial monitoring and approval of final report.

Jeremy Horwood (University of Bristol) was the senior qualitative researcher, and contributed to the protocol development, study management group member, qualitative analysis, writing and approval of final report.

Peter S Blair (University of Bristol) was the senior statistician, and contributed to the protocol development, study management group, statistical analysis, writing and approval of final report.

William Hollingworth (University of Bristol) was the senior health economist, and contributed to the protocol development, study management group, health economic analysis, writing and approval of final report.

Victoria Wilson (University of Bristol) was the trial manager and study management group member, and contributed to the trial monitoring, writing and approval of final report.

Chris Metcalfe (University of Bristol) was the senior trials methodologist, and contributed to the study management group, writing and approval of final report.

Peter Stoddart (Bristol Royal Hospital for Children) was a study management group member, and contributed to the secondary care expertise, protocol development and approval of final report.

Desmond Nunez (University of British Columbia) was a study management group member, and contributed to the primary care expertise, protocol development, writing and approval of final report.

Mark D Lyttle (Bristol Royal Hospital for Children) was a study management group member, and contributed to the secondary care expertise, protocol development, approval of final report.

Paul Little (Southampton University) was a study management group member, and contributed to the primary care expertise, protocol development and approval of final report.

Michael V Moore (Southampton University) was the principal investigator for the Southampton Centre and was a study management group member, and contributed to the primary care expertise, protocol development, trial monitoring, writing and approval of final report.

Publication

- Q44** Are topical antibiotics an alternative to oral antibiotics for children with acute otitis media and ear discharge? *BMJ*

Data-sharing statement


All data requests should be submitted to the corresponding author for consideration. Access to anonymised data may be granted following review.

References

1. Gulliford MC, Dregan A, Moore MV, Ashworth M, Staa Tv, McCann G, *et al.* Continued high rates of antibiotic prescribing to adults with respiratory tract infection: survey of 568 UK general practices. *BMJ Open* 2014;**4**:e006245. <https://doi.org/10.1136/bmjopen-2014-006245>
2. Hawker JI, Smith S, Smith GE, Morbey R, Johnson AP, Fleming DM, *et al.* Trends in antibiotic prescribing in primary care for clinical syndromes subject to national recommendations to reduce antibiotic resistance, UK 1995–2011: analysis of a large database of primary care consultations. *J Antimicrob Chemother* 2014;**69**:3423–30. <https://doi.org/10.1093/jac/dku291>
3. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. *BMJ* 2010;**340**:c2096. <https://doi.org/10.1136/bmj.c2096>
4. Lietzau S, Raum E, von Baum H, Marre R, Brenner H. Household contacts were key factor for children's colonization with resistant *Escherichia coli* in community setting. *J Clin Epidemiol* 2007;**60**:1149–55. <https://doi.org/10.1016/j.jclinepi.2007.01.016>
5. Fornasini M, Reves RR, Murray BE, Morrow AL, Pickering LK. Trimethoprim-resistant *Escherichia coli* in households of children attending day care centers. *J Infect Dis* 1992;**166**:326–30. <https://doi.org/10.1093/infdis/166.2.326>
6. Department of Health and Social Care. *UK Five Year Antimicrobial Resistance Strategy 2013 to 2018*. London: Department of Health and Social Care; 2013.
7. Rovers MM, Glasziou P, Appelman CL, Burke P, McCormick DP, Damoiseaux RA, *et al.* Antibiotics for acute otitis media: a meta-analysis with individual patient data. *Lancet* 2006;**368**:1429–35. [https://doi.org/10.1016/S0140-6736\(06\)69606-2](https://doi.org/10.1016/S0140-6736(06)69606-2)
8. National Institute for Health and Care Excellence (NICE). *Clinical Knowledge Summary: Acute Otitis Media*. NICE; 2013.
9. Venekamp RP, Sanders SL, Glasziou PP, Del Mar CB, Rovers MM. Antibiotics for acute otitis media in children. *Cochrane Database Syst Rev* 2015;**6**:CD000219. <https://doi.org/10.1002/14651858.CD000219.pub4>
10. Thompson PL, Gilbert RE, Long PF, Saxena S, Sharland M, Wong IC. Effect of antibiotics for otitis media on mastoiditis in children: a retrospective cohort study using the United Kingdom general practice research database. *Pediatrics* 2009;**123**:424–30. <https://doi.org/10.1542/peds.2007-3349>
11. Hoberman A, Paradise JL, Reynolds EA, Urkin J. Efficacy of Auralgan for treating ear pain in children with acute otitis media. *Arch Pediatr Adolesc Med* 1997;**151**:675–8. <https://doi.org/10.1001/archpedi.1997.02170440037006>
12. Bolt P, Barnett P, Babl FE, Sharwood LN. Topical lignocaine for pain relief in acute otitis media: results of a double-blind placebo-controlled randomised trial. *Arch Dis Child* 2008;**93**:40–4. <https://doi.org/10.1136/adc.2006.110429>
13. Sarrell EM, Cohen HA, Kahan E. Naturopathic treatment for ear pain in children. *Pediatrics* 2003;**111**:e574–9. <https://doi.org/10.1542/peds.111.5.e574>
14. Foxlee R, Johansson A, Wejfalk J, Dooley L, Mar Del C. Topical analgesia for acute otitis media (Review). *Cochrane Database Syst Rev* 2011;**19**:CD005657.

15. Ratcliffe J, Flynn T, Terlich F, Stevens K, Brazier J, Sawyer M. Developing adolescent-specific health state values for economic evaluation: an application of profile case best-worst scaling to the Child Health Utility 9D. *Pharmacoeconomics* 2012;**30**:713–27. <https://doi.org/10.2165/11597900-000000000-00000>
16. Dakin H, Petrou S, Haggard M, Bengt S, Williamson I. Mapping analyses to estimate health utilities based on responses to the OM8–30 Otitis Media Questionnaire. *Qual Life Res* 2010;**19**:65–80. <https://doi.org/10.1007/s11136-009-9558-z>
17. Ashworth M, Charlton J, Ballard K, Latinovic R, Gulliford M. Variations in antibiotic prescribing and consultation rates for acute respiratory infection in UK general practices 1995–2000. *Br J Gen Pract* 2005;**55**:603–8.
18. Williamson I, Bengt S, Mullee M, Little P. Consultations for middle ear disease, antibiotic prescribing and risk factors for reattendance: a case-linked cohort study. *Br J Gen Pract* 2006;**56**:170–5.
19. Little P, Gould C, Williamson I, Moore M, Warner G, Dunleavey J. Pragmatic randomised controlled trial of two prescribing strategies for childhood acute otitis media. *BMJ* 2001;**322**:336–42. <https://doi.org/10.1136/bmj.322.7282.336>
20. Smith R, Coast J. The true cost of antimicrobial resistance. *BMJ* 2013;**346**:f1493. <https://doi.org/10.1136/bmj.f1493>
21. Organisation for Economic Co-operation and Development. *Purchasing Power Parities*. 2016. URL: <https://data.oecd.org/conversion/purchasing-power-parities-ppp.htm> (accessed 15 December 2017).
- Q45** 22. Joint Formulary Committee. *British National Formulary*. London: BMJ Group and Pharmaceutical Press; 2014.
- Q46** 23. Curtis L. *Unit Costs of Health and Social Care 2011*. Canterbury: Personal Social Services Research Unit, University of Kent; 2011.
- Q47** 24. National Institute for Health and Care Excellence (NICE). *BNF*. 2017. <https://bnf.nice.org.uk/> (accessed 15 December 2017).
- Q48** 25. Noble M, McLennan D, Wilkinson K, Whitworth A, Barnes H, Dibben C. *The English Indices of Deprivation 2007. Communities and Local Government Publications*; 2008.
26. Sandelowski M. Sample size in qualitative research. *Res Nurs Health* 1995;**18**:179–83. <https://doi.org/10.1002/nur.4770180211>
- Q49** 27. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol* 2006;**3**. <https://doi.org/10.1191/1478088706qp063oa>
28. Boyatzis R. *Transforming Qualitative Information: Thematic Analysis and Code Development*. Sage, CA: Thousand Oaks; 1998.
29. Glaser B, Strauss A. *The Discovery of Grounded Theory: Strategies for Qualitative Research*. New York, NY: Aldine; 1967.
30. Charmaz K. *Constructing Grounded Theory: A Practical Guide Through Qualitative Analysis*. London: Sage; 2006.
31. Fergusson D, Aaron SD, Guyatt G, Hébert P. Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. *BMJ* 2002;**325**:652–4. <https://doi.org/10.1136/bmj.325.7365.652>
- Q50** 32. Oppong R, Smith RD, Little P, Verheij T, Butler CC, Goossens H, et al. Cost-effectiveness of amoxicillin for lower respiratory tract infections in primary care: an economic evaluation accounting for the cost of antimicrobial resistance. *Br J Gen Pract* 2016;**66**:e633–9. <https://doi.org/10.3399/bjgp16X686533>

Q51 Appendix 1 Recruitment to the CEDAR trial



Q52, Q53 **FIGURE 10** Projected and actual recruitment to the CEDAR trial, October 2016 to April 2017. Between October and December 2016, prior to the supply of IMP running low, randomisations to the two-group study reached target.

QUERIES TO THE AUTHOR

- Q1: Please let us know of any dual publications that you have submitted to any other journals or are preparing for submission at this time. Please note that we cannot hold any article in production without express permission from NIHR; therefore, if you feel this will be necessary for any publication, please contact NIHR and let us know once permission has been granted.
If copyright permission is required for any reproduced material from your dual publications, please seek this as early as possible to avoid any delays.
- Q2: Lignocaine has been changed to the BAN name lidocaine throughout. OK?
- Q3: Please could you confirm if your report contains patient data? If so, please confirm if you are happy for the following standard text to be inserted in the Acknowledgements section of your report:
This work uses data provided by patients and collected by the NHS as part of their care and support. Using patient data is vital to improve health and care for everyone. There is huge potential to make better use of information from people's patient records, to understand more about disease, develop new treatments, monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone's privacy, and it's important that there are safeguards to make sure that it is stored and used responsibly. Everyone should be able to find out about how patient data are used. #datasaveslives
You can find out more about the background to this citation here: <https://understandingpatientdata.org.uk/data-citation>.
- Q4: CEDAR is defined as 'The Children's Ear Pain Study' in the list of abbreviations. Please clarify which definition should be used throughout.
- Q5: This section is not typical in CONSOR-compliant abstracts. Should it be retained?
- Q6: Please clarify if this should be included as funding here and in the scientific summary? If so, please provide further details regarding the number in brackets.
- Q7: ID identifier added to list. OK?
- Q8: The journal style guidelines specify that drugs should be referred to by the generic name (followed by trade and manufacturer names in parentheses) at first mention in the main text, e.g. oseltamivir (Tamiflu®, Roche). Please provide the necessary details for Auralgan if appropriate.
- Q9: Please provide city/town and country location details.
- Q10: Please provide full reference details for this study to be inserted here in full.
- Q11: Please provide full reference details for these guidelines.
- Q12: Should this be hydroxyquinoline sulphate?
- Q13: The journal style guidelines specify that drugs should be referred to by the generic name (followed by trade and manufacturer names in parentheses) at first mention in the main text, e.g. oseltamivir (Tamiflu®, Roche). Please provide the necessary details for:
benzocaine-phenazone otic solution and
hydroxyquinolone sulphate, if appropriate.
- Q14: Text amended to clarify the options of allocation. Is this correct?
- Q15: Please define CHU-9D and OMQ-14.
- Q16: Please check text for sense.
- Q17: The words gender and sex both have the sense 'the state of being male or female'. However, they are typically used in slightly different ways: sex tends to refer to biological differences, whereas gender refers to cultural or social differences. Should the term 'gender' be changed to 'sex' throughout the report?
- Q18: Can 'points' be added as the unit throughout?
- Q19: Text added to clarify why the following list totals more than 11. Is this correct?
- Q20: Please provide the authors' names, their main institution and year of communication for this unpublished source.
- Q21: Please provide the reference number for these guidelines.
- Q22: Please provide a reference for these guidelines.
- Q23: The journal style guidelines specify that drugs should be referred to by the generic name (followed by trade and manufacturer names in parentheses) at first mention in the main text, e.g. oseltamivir (Tamiflu®, Roche). Please provide the necessary details for procaine, tetracaine if appropriate.
- Q24: Please define SRQ.
- Q25: The journal style guidelines specify that drugs should be referred to by the generic name (followed by trade and manufacturer names in parentheses) at first mention in the main text, e.g. oseltamivir (Tamiflu®, Roche). Please provide the necessary details for amoxicillin if appropriate.

- Q26: The journal style guidelines specify that drugs should be referred to by the generic name (followed by trade and manufacturer names in parentheses) at first mention in the main text, e.g. oseltamivir (Tamiflu®, Roche). Please provide the necessary details for Otomize drops if appropriate.
- Q27: Should this be > 2 years of age for clarity?
- Q28: All tables: Headings for column 1 have been inserted for all tables. Please check all and confirm OK.
- Q29: Please provide a definition for this footnote.
- Q30: Tables 2a and b and Tables 3a and b have been renumbered to Tables 2–5. OK.
- Q31: Can a reference be provided for this?
- Q32: Tables 12–14: Is this value in this column a 95% CI?
- Q33: The journal style guidelines specify that drugs should be referred to by the generic name (followed by trade and manufacturer names in parentheses) at first mention in the main text, e.g. oseltamivir (Tamiflu®, Roche). Please provide the necessary details for Otrivine if appropriate.
- Q34: Legend amended for figure parts a–e. OK?
- Q35: Please provide axes titles.
- Q36: Text amended to clarify use of 'latter'. OK?
- Q37: Please provide a reference for NHS 111 and ONS.
- Q38: The journal style guidelines specify that drugs should be referred to by the generic name (followed by trade and manufacturer names in parentheses) at first mention in the main text, e.g. oseltamivir (Tamiflu®, Roche). Please provide the necessary details for Calpol if appropriate.
- Q39: Here and below, can 'glycerol drops' be changed to 'placebo drops'?
- Q40: The journal does not publish policy recommendations. Please check this section and modify if necessary. Please note that this text will also be highlighted for editorial approval.
- Q41: UKCRC and CTU expanded. OK?
- Q42: This section has been moved to here from Chapter 1. OK?
Should any information here be moved to the funding sections of the abstract or scientific summary?
- Q43: Text amended to sentences. Please check all and confirm OK.
- Q44: Please provide full reference details.
- Q45: Can an edition be provided?
- Q46: Reference updated, is this correct?
- Q47: Please check if these details are correct?
- Q48: Please provide a publisher and location details, or a URL and accessed date.
- Q49: Please provide a page range.
- Q50: The page range and volume has been amended to match that in PubMed; OK?
- Q51: Appendix heading added. OK?
- Q52: Please provide axes titles.
- Q53: This figure has been renumbered consecutively from figures in the main text, in accordance with journal style. OK?